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In the recent years a growing amount of evidence indicates the functional significance 
of epigenetics in various aspects of neural function and dysfunction. Alterations in 
chromatin structure resulting in long lasting changes in gene expression have been 
associated to many different aspects of neuronal biology, including neurodegenerative 
disorders such Amyotrophic Lateral Sclerosis (ALS). ALS is predominantly sporadic 
and environmental triggers may be involved in disease initiation. In this respect, the 
epigenome can provide the key to transform the genetic information into phenotype. 
Alterations in the epigenetic machinery and/or epigenetic modifications can be 
considered a readout of disease onset and progression and an ideal target for therapeutic 
interventions. My PhD thesis is, indeed, focused on different aspect of epigenetic 
modifications in ALS cellular and animal models. By in vitro and in vivo assays I 
demonstrate that some epigenetic markers, linked to transcriptional activation or 
repression, are selectively altered in cellular and animal model of ALS. Moreover I 
observed a physical interaction between the ALS-causing gene TDP43 and the histone 
deacetylases 1 (HDAC1). Finally, I demonstrate that perturbation of HDAC1 level or 
activity affects TDP-43-induced cell damage. Although preliminary, these data can be 
extended by testing more specific HDAC1 inhibitors which can be chemically 
optimized by computational biology approaches. 
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1.1 AMYOTHOPHIC LATERAL SCLEROSIS (ALS) 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by 
the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal 
paralysis. ALS usually begins with asymmetric involvement of the muscles of one or 
more limbs, speech or deglutition in middle adult life. The involvement appears to 
spread in an anatomically contiguous manner and eventually becomes bilateral and 
symmetrical, progressing to paralysis and death. Mean survival is 3 years after the onset 
of symptoms (Chio, Logroscino et al. 2009). Classical clinical classification proposed 
three phenotypic forms of familial ALS, each inherited as an autosomal dominant 
disorder. The first form they delineated is characterized by rapidly progressive loss of 
motor function with predominantly lower motor neuron manifestations and a course of 
less than 5 years. Pathologic changes are limited to the anterior horn cells and pyramidal 
tracts. The second form is clinically identical to the first, but at autopsy additional 
changes are found in the posterior columns, Clarke column, and spinocerebellar tracts. 
The third form is similar to the second except for a much longer survival, usually 
beyond 10 and often 20 years (Meyer, Schwan et al. 2005). 
 
 
Figure 1. Motor neurons selectively affected in ALS. Degeneration of motor neurons in the motor 
cortex leads to clinically apparent signs of upper motor neuron abnormalities. Degeneration of motor 
neurons in the brain stem and spinal cord causes muscle atrophy, weakness and fasciculation. 
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Anyway, more recently, clinicians prefer to analyze the complete phenotypic criteria 
and to formulate a diagnosis basing on continuous variations on the severity of the 
symptoms, without distinguishing in ALS forms (Rutter-Locher, Turner et al. 2016).  
Al Chalabi and colleagues proposed a new classification method that combines the 
classical diagnostic approach based on El Escorial categories with the rich variety of 
phenotypic descriptions (Al-Chalabi, Hardiman et al. 2016).  
 
Figure 2. Classification system for amyotrophic lateral sclerosis (Al-Chalabi, Hardiman et al. 2016) 
 
Population based studies have established that the incidence of ALS in Europe is fairly 
uniform at 2,16 per 100 000 person-years (Logroscino, Traynor et al. 2010). Although 
ALS affects people worldwide, an exact incidence of this disease is not yet known. Men 
have a higher incidence of disease (3,0 per 100 000 person-years; 95% CI 2,8–3,3) than 
do women (2,4 per 100 000 person-years; 95% CI 2,2–2,6), although the incidence 
between men and women is about the same in familial disease. 
1.1.1 ALS etiology: a multifactorial perspective 
 
ALS etiology has been recognized to be multifactorial (Vucic and Kiernan 2009). It 
occurs as an apparently sporadic disease (sALS) in 90% of cases; while the residual10% 
of ALS cases are familial (fALS) and linked to a specific gene mutation (Beleza-
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Meireles and Al-Chalabi 2009). In sALS, environmental factors may contribute to the 
pathology, i.e. lesions in frontotemporal lobes or exposition to some pesticides like 
organochlorine insecticides aldrin or toxaphene have been linked to the development of 
the disease (Kamel, Umbach et al. 2012).  
1.1.2 Genetic factors 
 
Approximately 10% of ALS is classified as familial, whereas the remaining 90% of the 
cases are considered sporadic, as they appear to occur randomly throughout the 
community.  
Since now, 22 locus have been linked to the development of ALS. Among them, the 
most studied are those displayed in table 1. 
 
Genes known to carry ALS-causing mutations 
   Percentage explained 
Putative protein function 
Gene Location Inheritance Familial ALS Sporadic ALS 
TARDBP 1p36 AD 4 1 RNA metabolism 
SQSTM1 5q35 AD 1 <1 Ubiquitination; 
autophagy 
C9ORF72 9p21 AD 40 7 DENN protein 
VCP 9p13 AD 1 1 Proteasome;vesicle 
trafficking 
OPTN 10p13 AR and AD <1 <1 Vesicle trafficking 
FUS 16p11 AD and AR 4 1 RNA metabolism 
PFN1 17p13 AD <1 <1 Cytoskeletal 
dynamics 
SOD1 21q22 AD and AR 12 1–2 Superoxide metabolism 
UBQLN2 Xp11 XD <1 <1 Proteasome 
Others<1 
Table1.Principal gene locus involved in ALS and relative mutations. 
 
SOD1 is the first historically discovered ALS causing gene (Rosen, Siddique et al. 
1993). Over than 200 point mutations have been reported on SOD1 gene. Nevertheless, 
SOD1 mutations account for the 12% of fALS and for the 1% of sALS.  
Locus 16p11 and locus 1p36 encode respectively for FUS and TDP43 protein, both 
involved in RNA metabolism. Together they are linked with the 8% of all fALS.  
In 2009 two research groups reported that a massive hexanucleotide repeat expansion in 
C9ORF72 is the cause of chromosome 9p21–linked ALS and FTD (DeJesus-
Hernandez, Mackenzie et al. 2011, Renton, Majounie et al. 2011). This pathogenic 
expansion accounts for a remarkable percentage of both familial ALS (~40%) and 
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familial FTD (~25%). In addition, the repeat expansion has been found to account ~7% 
of apparently sporadic ALS cases in people of European ancestry, marking the first time 
that a genetic etiology has been identified for more than just the occasional sporadic 
case (Renton, Chio et al. 2014). 
 
1.1.2.1 ALS1: Superoxide dismutase 1 (SOD1) 
21q22 gene locus encodes for a 32 kD homodimeric protein called Cu/Zn SOD1. It is 
the major cytoplasmic antioxidant enzyme that metabolizes superoxide radicals to 
molecular oxygen and hydrogen peroxide, thus providing a defense against oxygen 
toxicity. It forms a β-barrel and contains an intramolecular disulfide bond and a 
binuclear Cu/Zn site in each subunit. This Cu/Zn site holds the copper and a zinc ion 
and is responsible for catalyzing the disproportion of superoxide to hydrogen peroxide 
and dioxygen (Niwa, Yamada et al. 2007).  
 
Figure 3.Structure and function of SOD1.A) SOD1 gene position on chromosome 21. B) 
Tridimensional structure of human SOD1. C) Active site of Cu/Zn SOD1. D) Mechanism cyclic 
oxidation-reduction catalyzed by SOD1. 
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Since the first description in 1993, more than 200 point mutations have been described, 
even if only a small percentage of them have been clearly linked to the pathology. In 
fALS linked to SOD1 mutations, the majority has a dominant inheritance, like G93A or 
H80R (Rosen, Siddique et al. 1993, Alexander, Traynor et al. 2002).  
The pathological mechanism linked to SOD1 is complex. Since some mutations concern 
the metal binding residues at the active site, while others may concern correct folding or 
stability of the homodimer, the biochemical and biophysical properties of ALS-
associated mutant SOD1 proteins are rather heterogeneous. In fact, studies on 
recombinant mutant SOD1 proteins have been proved that ALS-associated SOD1 
mutations can be attributed at two mutant classes, the "wild-type like" (WTL) SOD1 
mutants which retain the ability to bind copper and zinc and exhibit normal specific 
activity, indicate a native-like structure with only subtle changes to the backbone fold, 
in contrast the "metal-binding region" (MBR) SOD1 mutants that are deficient in copper 
and zinc and exhibit severe thermal destabilization and structural disorder of conserved 
loops near the metal-binding sites. G93A and H80R-SOD1 mutants belong respectively 
to the two classes of mutants described above (Tiwari and Hayward 2005). 
To date, different hypothesis have been made to explain SOD1 toxicity. The 
aggregation hypothesis is particularly attractive because protein aggregates are 
frequently associated with neurodegenerative diseases such as ALS. Numerous studies 
revealed that SOD1 mutant is incline to misfolding and to form cytoplasmic aggregates 
(Rotunno and Bosco 2013). In turn, these aggregates could lead to cell death by 
sequestering other cytoplasmic proteins essential for neuronal survival, by clogging the 
ubiquitin/proteasome system, by chaperones depletion, or by disrupting mitochondria, 
cytoskeleton and/or axonal transport. Another hypothesis is that SOD1 misfolding 
induced by mutations would allow the access of abnormal substrates such as 
peroxynitrite to the catalytic site leading to the nitration of tyrosine residues (Beckman, 
Carson et al. 1993, Rotunno and Bosco 2013). 
1.1.2.2 ALS6: FUS 
Mutations in 16p11.2 locus encoding for FUS protein have been linked to a familiar 
form of ALS (Kwiatkowski, Bosco et al. 2009). FUS is a 75 kDa nuclear protein. It is 
ubiquitously expressed. FUS/TLS is a 526 amino acid protein encoded by 15 exons and 
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characterized by an N-terminal domain enriched in glutamine, glycine, serine and 
tyrosine residues (QGSY region), a glycine-rich region, an RRM domain, multiple 
arginine/glycine/glycine (RGG) repeats in an arginine and glycine-rich region and a C-
terminal zinc finger motif. Most of the mutations are clustered in the glycine-rich region 
and in the extreme C-terminal part of the protein with evidence for mutations in each of 
the five arginine residues (Deng, Gao et al. 2014). Thirty mutations have now been 
reported in 4% of familial ALS and in rare sporadic patients with no apparent familial 
history. The inheritance pattern is dominant except for one recessive mutation (H517Q) 
found in a family of Cape Verdean origin. Most are missense mutations with a few 
exceptions (Kwiatkowski, Bosco et al. 2009). 
 
Figure 4.Genomic and structural organization of human FUS gene and protein.FUS gene is encoded 
by 15 exons that cover an 11.6 kb region on chromosome 16p11.2. QGSY rich: serine–tyrosine–glycine–
glutamine rich domain; RRM: RNA recognition motif; ZnF: cysteine2/cysteine2 zinc finger motif; RGG 
rich: arginine–glycine–glycine rich domain.(Adapted from(Deng, Gao et al. 2014) 
FUS functions are multiple and not completely understood. Many studies enlighten that 
FUS binds to single-strand and double-strand RNA; FUS seems to act at various levels 
in RNA metabolism, including transcription, splicing and translation (Prasad, Ouchida 
et al. 1994). In addition, FUS acts as a transcriptional regulator. FUS associates with 
products of RNA polymerase II transcription, forms complexes with hnRNPs, and 
represses RNA polymerase III transcription. Furthermore, FUS inhibits the 
acetyltransferase activities of CREB-binding protein (CBP) and p300 on cyclin D1 
(CCND1) (Wang, Arai et al. 2008) and regulates the transcription factor nuclear factor 
kB (NF-kB) (Goransson, Andersson et al. 2009). FUS also engages in rapid nucleo-
cytoplasmic shuttling, associates with actin-dependent motor protein myosin Va 
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(MyoVa) (Yoshimura, Fujii et al. 2006), and is a component of RNA granules that 
transport mRNAs (Belly, Moreau-Gachelin et al. 2005). 
Many insights into FUS function come out studying FUS interactome with different 
experimental approach in a variety of models. FUS has been demonstrated to directly 
bind (i) to the U1-snRNP, reducing RNA processing, and SMN complexes activity; 
(Sun, Ling et al. 2015), (ii) to the C-terminal domain (CTD) of RNA polymerase II 
(RNA Pol II) in an RNA-dependent manner (Schwartz, Ebmeier et al. 2012), (iii) to the 
heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and hnRNPA2B1 (Takanashi and 
Yamaguchi 2014), (iv) to histone deacetylase 1 (HDCA1) during DNA repair (Wang, 
Pan et al. 2013). 
1.1.2.3 ALS10: TDP43 
TDP-43 is a multifunctional protein involved in gene expression and regulation, 
including transcription, RNA splicing, transport, and translation. It is ubiquitously 
expressed, nuclear, 43 kDa. It is a multidomain protein: it has a N-terminal domain, 
with a NLS signal, two RRM domains (RRM1 and RRM2) and a glycine-rich domain, 
in the C-terminus of the protein. The majority of the mutations are localized in the C-
terminal part of TDP43 (Sreedharan, Blair et al. 2008). 
TDP-43 is also involved in the processing of small regulatory RNAs (micro RNAs) and 
in RNA maturation and splicing. TDP43 is a major component of the ubiquitin-positive 
neuronal inclusions that are the pathological hallmark of both ALS and frontotemporal 
dementia (FTD) (Neumann, Sampathu et al. 2006).  
Mutations in TDP43 are responsible of 4–6% of familial and 0.7–2% of sporadic ALS. 
Although TDP43 mutations are found in ALS families across the globe, some regional 
variability does exist. For example, the A382T mutation of the protein is particularly 
frequent in Sardinia, reflecting the conserved nature of that island population combined 
with a historical founder effect (Chio, Borghero et al. 2011). 
Mutations in TDP43 are mainly located with-in the C-terminal glycine-rich domain of 
the protein. Although the pathophysiological mechanisms by which TDP43 gene 
mutations result in neurodegeneration remain to be defined fully, emerging evidence 
suggests multiple mechanisms including gain of toxicity, loss of nuclear function, and 
the formation of large stress granules. Support for a toxic gain of function has been 
provided by studies in transgenic mouse models wherein increased expression of the 
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mutated TDP43 proteins leads to neurodegeneration through dysfunction of cellular 
organelles and proteins (Lee, Lee et al. 2011). The severity of cortical and spinal motor 
neuron degeneration appears to be proportional to TDP43 protein levels, suggesting a 
potential role for TDP-43 in regulating disease severity (Wils, Kleinberger et al. 2010). 
Alternatively, loss of nuclear TDP43 accompanied by accumulation of TDP43 
aggregates in the cytoplasm has been well established in ALS patients, implying a 
potential role for a TDP43 loss of nuclear function mechanism in ALS pathogenesis 
(Lee, Lee et al. 2011). Of further relevance, TDP43 associates with cytoplasmic stress 
granules (McDonald, Aulas et al. 2011). Specifically, stress granules function to 
suppress mRNA translation temporarily and store pre-RNA complexes during periods 
of cellular stress, thereby safeguarding the coded RNA information from deleterious 
chemicals. Pathological TDP43 mutant protein appears to exhibit a greater propensity to 





Figure 5.TDP43 mutations in ALS. Forty-four mutations have been identified in TDP43 in sporadic and 
familial ALS patients, with most lying in the C-terminal glycine-rich region. All are missense mutations, 
except for the truncating mutation TDP43
Y374X
. Adapted from (Lagier-Tourenne, Polymenidou et al. 
2010). 
TDP43 interacts with a large amount of RNAs and proteins. For example, the glycine-
rich C-terminus of TDP-43 has been shown to mediate interaction with several hnRNP 
proteins, specifically hnRNPs A1, A2/B1, C1/C2, and A3 (Buratti, Brindisi et al. 2005). 
TDP-43 interacts with nuclear and cytoplasmic proteins, and these interactions are often 
RNA-dependent. Freibaum and Chitta elaborated an interactome of TDP43, recognizing 
two classes of TDP43 binding protein: the first is a network of nuclear proteins that 
regulate RNA splicing and other aspects of nuclear RNA metabolism, and the second is 
a network of cytoplasmic proteins that regulate mRNA translation (Freibaum, Chitta et 
al. 2010). Moreover, they demonstrated that TDP43 pathological mutations M337V and 
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A315T do not alter the interaction. TDP43 interacts also with FUS (Ling, Albuquerque 
et al. 2010). TDP43 and FUS directly interact in a RNA/protein complex with HDAC6, 
regulating its expression levels (Kim, Shanware et al. 2010). TDP43 and HDAC6 
interaction was demonstrated by Hebron and colleagues in 2013 (Hebron, Lonskaya et 
al. 2013).  
Another interesting point to discuss is TDP43 changing functions when acetylated. As 
for others transcription factor, acetylation is one of the most important control 
mechanism. A well studied example is p53, whom acetylation has many important 
effects. It increases p53 protein stability, binding to low affinity promoters, association 
with other proteins, antiviral activities, and is required for its checkpoint responses to 
DNA damage and activated oncogenes (Reed and Quelle 2014). Since now, few is 
known about TDP43 acetylation. Cohen and colleagues demonstrated that TDP-43 
acetylation impairs RNA binding and promotes accumulation of insoluble, hyper-
phosphorylated TDP-43 species that largely resemble pathological inclusions in ALS 
and FTLD-TDP (Cohen, Hwang et al. 2015). 
1.1.3 Environmental factors 
 
In ALS onset and progression the interaction between genetic background and external 
factors is thought to play a major role (Bozzoni, Pansarasa et al. 2016). Exposure to 
heavy metals, such as lead, selenium, mercury, cadmium and iron, as a risk factor for 
ALS has long been studied, and the results produced are contradictory. Exposure to 
selenium has been largely studied and results indicate that there are in vitro evidences 
but not any statically significant association. Similar results emerged in studies about 
mercury and lead (Trojsi, Monsurro et al. 2013). Another factor that has recently been 
linked to sALS is the exposure to electromagnetic fields (EFMs), especially to low 
frequency EFMs. Despite interesting initial evidences, no any significant association 
has emerged in the latest studies (Vergara, Mezei et al. 2015). Exposure to a various 
spectrum of substances has been largely investigated. Cyanobacteria produce several 
cyanotoxins, divided into neurotropic (e.g. BMAA) and hepatotropic, such as cycasin, 
whose carcinogenic potential is well documented. The hypothesis that BMAA may have 
a role in neurodegenerative diseases was initially based on reports of elevated rates of 
ALS, Parkinson‟s disease and dementia in the island of Guam, where cycad seeds are 
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used to produce flour containing a remarkable amount of BMAA. Increased brain levels 
of BMAA were found in Guam ALS patients and similar BMAA levels were also found 
in the brains of ALS patient in Florida (Pablo, Banack et al. 2009). The latest in vivo 
studies confirm that BMAA can be incorporated into nerve cell proteins, causing 
misfolding, aggregates and cell death (Dunlop, Cox et al. 2013). BMAA role in causing 
worldwide sALS needs to be more detailed studied. Pesticides and precisely insecticides 
are the earlier studied fALS cause. Some of them, particularly organophosphate 
pesticides, can cause neurological damage, due to inhibition of acetylcholinesterase, the 
enzyme responsible for terminating the biological activity of acetylcholine. Moreover, 
most of these chemical compounds are known for their ability to induce oxidative 
stress, mitochondrial dysfunction, α-synuclein storage and neuronal loss.  
Environmental toxins Effect 
Cigarette smoke Increase the probability of developing ALS through inflammation, 
oxidative stress, and neurotoxicity by heavy metals contained in 
cigarettes. 
Heavy metals Lead: greater tibia and blood Pb levels were found to be associated with 
increased survival of ALS patients 
Mercury: Diet organic mercury, through fish and derivates, and 
occupational exposure have been shown to be linked to ALS onset. 
Selenium: Se exposure may considerably influence SOD1 accumulation 
into mitochondria, a somatic feature occurring in neurons during ALS 
pathogenesis. 
Physical activity Several genes (i.e., ciliary neurotrophic factor, leukemia inhibitory 
factor, and vascular endothelial growth factor 2) related to exercise have 
been recognized as possible ALS risks factors. 
Agricultural chemicals ALS risk is associated with use of organochlorine insecticides (e.g., 
dichloro-diphenyl-trichloroethane), pyrethroids, herbicides, and 
fumigants but not with other pesticide classes 
Radiation/electromagnetic 
fields 
Electromagnetic fields cause DNA strands to break in brain cells, leading 
to cell death and such reaction could be the reason for the association 
between electromagnetic fields and ALS risk. 
Diet Consuming high level of glutamate and fat can have adverse effects on 
ALS patients while Omega 3 fatty acids, Vitamin E, and fiber can have 
defensive impact. 
Table 2. Environmental factors linked to ALS risk and pathophysiology. Adapted from (Zarei, 
Carr et al. 2015). 
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This data emerges by the more elevated risk to develop ALS in farmers, employees of 
chemical industries, inhabitants in rural areas (McGuire, Garrison et al. 1997). A big 
amount of case-control studies confirm that pesticides exposure is a risk factor for sALS 
(Sutedja, Fischer et al. 2009). ALS owes its colloquial name to baseball player Lou 
Gehrig, who contracted ALS at the age of 27 in 1939. A cohort study conducted on 
24000 soccer player Italian players evidences that there is a high prevalence of ALS, 
approximately 5 or 6 folds more than global population. Causes are unclear yet, but 
many were postulated. Football players may be exposed to various risk factors that 
could contribute to neurodegenerative processes, namely excessive physical activity, 
repeated head injuries, exposure to pesticides and dietary supplements or illegal 
substances. 
1.1.4 ALS experimental models 
 
In order to better understand the pathophysiological processes of the ALS onset, several 
model systems have been created over the years such as cell lines and transgenic 
animals, expressing different ALS-causative genes (SOD1, FUS and TDP43) in the wild 
type form or with the several pathological mutations. Among the mammalian animal 
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Table 3. Characteristic of the most used mammalian animal and cellular models for ALS  
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1.1.5 Pathogenic mechanisms 
 
Understanding ALS pathogenesis appears to be central for future development of 
diagnostic and therapeutic strategies in ALS. Pathogenesis of ALS is complex and many 
processes seem to contribute to the development of the disease. In vitro studies show 
that synaptosomes in neural tissue display a marked decrease in the maximal velocity of 
transport for high-affinity glutamate uptake in spinal cord, motor cortex, and 
somatosensory cortex compared to controls. The decrease in glutamate uptake was not 
observed in tissue from visual cortex, striatum, or hippocampus (Rothstein, Martin et al. 
1992).Oxidative stress is another pathway lined to neurodegeneration in ALS. SODl 
mutations have been shown to enhance in vitro generation of hydroxyl radical from 
hydrogen peroxide. In addition to the dismutation of superoxide to hydrogen peroxide, 
wild-type CuZn-SOD1 can use hydrogen peroxide as a substrate to initiate a Fenton-like 
reaction with production in vitro of hydroxyl radical (Liu, Althaus et al. 1998). Several 
evidences report a link between protein misfolding and ALS. In particular, SOD1 mutations 
induce conformational instability and misfolding of the SOD1 peptide, resulting in 
formation of intracellular aggregates that inhibit normal proteosomic function, 
disrupting axonal transport systems and vital cellular functions (Zetterstrom, Stewart et 
al. 2007). Recently, a functional study demonstrated that mutant ineffective Hsp104 
impairs SOD1 or TDP43 aggregation and lead to the disgregation of misfolded 
aggregates (Jackrel and Shorter 2014). Of further relevance, TDP-43 was recognized as 
a major component of ubiquitinated cytoplasmic protein aggregates in almost all 
patients with sporadic ALS, but not in the nucleus, as in normal neurons. Given that 
TDP43 binds both DNA and RNA, mutations in TDP43 could result in deregulation of 
RNA processing (Arnold, Ling et al. 2013). As with TDP43, the finding of cytoplasmic 
FUS-positive inclusions in ALS patients also implies loss of nuclear function as a 
potential pathogenic mechanism, and is supported by FUS expression studies in 
transgenic mouse models. Conversely, a toxic-gain of function has also been inferred 
from FUS expression studies. Of further relevance, TDP-43 and FUS associate with 
cytoplasmic stress granules. Specifically, stress granules function to suppress mRNA 
translation temporarily and store pre-RNA complexes during periods of cellular stress, 
thereby safeguarding the coded RNA information from deleterious chemicals (Van 
Deerlin, Leverenz et al. 2008). The role of RAN-proteins, for example the possible 
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translation of C9Orf72 RNA, have recently been studied in ALS context. (Cleary and 
Ranum 2014). RAN translation of the sense GGGGCC expansion is predicted to result 
in the expression of three dipeptide proteins: GlyPro (GP), GlyArg (GR) and GlyAla 
(GA). Support for the accumulation of RAN-proteins in C9ORF72 ALS/FTD autopsy 
brains was reported using antibodies against the predicted dipeptide repeat motifs (GP, 
GR and GA).Structural and functional abnormalities of mitochondria, impairment of 
axonal transport systems and endosomal trafficking, together with neuroinflammation 
and induction of the endoplasmic reticulum stress response, have all been implicated in 
ALS pathogenesis. Although these mechanisms contribute to neurodegeneration, they 
appear to be secondary events in ALS (Ferraiuolo, Kirby et al. 2011).  
 
Figure 6.ALS in a multifactorial disease. Pathway involved are formation of SOD1 and TDP43 
misfolded aggregates, increased oxidative stress, neuroinflammation, impaired glutamate uptake, 
glutamate excitotoxicity (Vucic, Rothstein et al. 2014). 
 
In addition, alterations in epigenetic regulation are implicated in ALS pathogenesis (Al-
Chalabi, Kwak et al. 2013). In fact in the last decade, the field of epigenomics has 
emerged, revealing that DNA modifications, including DNA-bound histones, DNA 
methylation, and chromatin remodeling, which may depend from environmental clues, 
such as lifestyle, diet and toxin exposure, also provide levels of gene regulation and 
alter gene expression. Epigenetic factors are probably much more suited than genetic 
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factors to explain disease onset and progression in ALS, since aberrant epigenetic, 
patterns may be acquired throughout life. In the next paragraphs I will review epigenetic 
modifications, focusing on their role in ALS.  
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1.2 EPIGENETICS  
 
1.2.1 The epigenetic machinery 
 
Historically, the word “epigenetics” was used to describe events that could not be 
explained by genetic principles. Conrad Waddington (1905–1975), who is given credit 
for coining the term, defined epigenetics as “the branch of biology which studies the 
causal interactions between genes and their products, which bring the phenotype into 
being” (Waddington 1959).The term epigenetics in its contemporary usage emerged in 
the 1990s, but for some years has been used in somewhat variable meanings (Berger, 
Kouzarides et al. 2009). A consensus definition of the concept of epigenetic trait as 
"stably heritable phenotype resulting from changes in a chromosome without alterations 
in the DNA sequence" was formulated at a Cold Spring Harbor meeting in 2008 
(Berger, Kouzarides et al. 2009). 
 
 
Figure 7.Waddington’s idea of epigenetics in 1942. 
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Epigenetics refers to patterns of gene expression that are heritable through cellular 
division (i.e., mitosis and meiosis) and are not directly attributed to any changes in the 
primary DNA sequence. Such effects on cellular and physiological phenotypic traits 
may result from external or environmental factors that switch genes on and off and 
affect how cells express genes. A wide variety of illnesses, behaviors, and other health 
indicators already have some level of evidence linking them with epigenetic 
mechanisms, including cancers of almost all types, cognitive dysfunction, and 
respiratory, cardiovascular, reproductive, autoimmune, and neurobehavioral illnesses 
(Goldberg, Allis et al. 2007). Known or suspected drivers behind epigenetic processes 
include many agents, including heavy metals, pesticides, diesel exhaust, tobacco smoke, 
polycyclic aromatic hydrocarbons, hormones, radioactivity, viruses, bacteria, and basic 
nutrients. 
Many types of epigenetic processes have been identified. The most well-known 
epigenetic mechanisms in humans are DNA methylation and post-translational 
modifications of histone proteins. Other epigenetic mechanisms and considerations are 
likely to surface as work proceeds. Epigenetic processes are natural and essential to 
many organism functions, but if they occur improperly, there can be major adverse 
health and behavioral effects. Perhaps the best known epigenetic process, in part 
because it has been easiest to study with existing technology, is DNA methylation, 
namely the addition or removal of a methyl group (CH3). DNA methylation was first 
confirmed to occur in human cancer in 1983, and has since then been observed in many 
other illnesses and health conditions. 
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Figure 8. Epigenetic regulation is a dynamic process. A class of epigenetic regulators are “the writers”, 
which modify chromatin laying down epigenetic marks on amino acid residues on histone tails. They are 
histone acetyltransferases (HATs), histone methyltransferases (HMTs), protein arginine 
methyltransferases (PRMTs) and kinases. The “epigenetic readers” such as proteins containing 
bromodomains, chromodomains and Tudor domains bind to these epigenetic marks and translate the 
messages. Finally, “epigenetic erasers” such as histone deacetylases (HDACs), lysine demethylases 
(KDMs) and phosphatases catalyse the removal of epigenetic marks. Addition and removal of these post-
translational modifications of histone tails leads to the addition and/or removal of other marks in a highly 
complicated histone code. Together, histone modifications regulate various DNA-dependent processes, 
including transcription, DNA replication and DNA repair. Adapted from (Falkenberg and Johnstone 
2014). 
 
Histone modifications involve multiple post-transcriptional alterations of the N-terminal 
tails of histone proteins such as acetylation, methylation and phosphorylation, which 
can contribute to the 'open' or 'closed' transcriptional state of the chromatin. DNA 
methylation and histone-modification events are tightly interconnected. Histone-
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modifying enzymes can recruit DNA-methylransferases to the genomic loci bearing a 
specific 'histone code' and, in turn, methylated DNA binding proteins can recruit 
histone-modifying enzymes to the hypermethylated loci, thus establishing a combined 
DNA/histone epigenetic mark self-perpetuated in cellular divisions. 
 
Figure 9. Epigenetic machinery in neurons. In healthy neurons or glia (left), transcriptionlly active 
gene promoter have unmethylated CpG island and a set of histone modifications associated with open 
“chromatin” conformation (eg, hyperacetylation and methylation of lysine 4 of histone H3). One the left, 
a neurodegenerated neuron carries “closed” chromatin conformation with dense hypermethylation of the 
CpG island promoter, repressive histone chemical modifications such as methylation of lysines 9 and 27 
of histone H3. Epigenetic drugs such as DNA-demethylating drugs and HDAC inhibitors can partially 
rescue the distorted epigenetic processes. Ac=acetylation. DNMT=DNA methyltransferase. HAT=histone 
acetyltransferase. HDAC=histone deacetylase. HDM=histone demethylase. HMT=histone 
methyltransferase. MBD=methyl-CpG binding domain protein. Met-K4=methylation of lysine 4. Met-
K9=methylation of lysine 9. Met-K27=methylation of lysine 27. SWI/SNF=switching/sucrose non 
fermenting chromatin-remodelling complex. Adapted from (Urdinguio, Sanchez-Mut et al. 2009).  
 
1.2.2 Covalent histone-tails post-translational modifications 
 
At the heart of chromatin structure are highly conserved histone proteins (H3, H4, H2A, 
H2B and H1) that function as building blocks to package eukaryotic DNA into 
repeating nucleosomal units that are folded into higher-order chromatin fibers. Covalent 
modifications of histone proteins play central roles in many types of epigenetic 
inheritance. The most common histone tails modifications are lysine acetylation, lysine 
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and arginine methylation, serine and threonine phosphorylation, but also lysine 
ubiquitination and sumoylation. The majority of this covalent modifications occurs in 
histone H3 and H4 tail (Strahl and Allis 2000). This modifications acts as an alphabet, a 
code that is read by protein complexes, which slide on DNA molecules and translate the 
code into a biological and physical response, which may be the switch to an active into 
a repressed state of the chromatin or vice versa. In addition, histone code differentially 
marks chromatin that is constitutively condensed, or facultative eterochromatin, which 
can be converted into a non-condensed form in certain moments of cell cycle.  
Every single modification has a determined significance if considered in the context in 
which it is localized. That is, a modification that acts as a repressive message, changing 
context, can change its meaning. In general, considering the electrostatic requirements 
for folding the chromatin polymer, histone acetylation, through the neutralization of 
positive charge, and histone phosphorylation, through the addition of negative charge, 
would probably cause decondensation of the chromatin. On the contrary, lysine and 
arginine methylation usually causes chromatin condensation.  
 
Figure 10. The most frequent covalent modifications on histone H3 and H4 tails and their relative 
meaning. S10 phosphorylation associated with K14 acetylation lead to transcriptional activation; K4 
dimethylation is associated with transcriptional activation; K9 and K27 methylation are associated with 
transcriptional repression. From (Strahl and Allis 2000). 
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As histone code is written by a variety of enzymes (see below), it is read by complex of 
proteins. Recent evidence shows that the bromodomain of human PCAF (P300/CBP-
associated factor), a domain of little known function which is shared between many, but 
not all HATs, binds acetylated lysine in the context of H3 and H4 tail sequences 
(Dhalluin, Carlson et al. 1999). For example, ATP-dependent chromatin remodeling 
complexes are specialized protein machinery able to restructure the nucleosome to make 
its DNA accessible during transcription, replication and DNA repair. ATP-dependent 
chromatin remodeling complexes specifically recognize these histones marks, and 
through ATP hydrolysis unwrap, mobilize, exchange or eject the nucleosome, and 
subsequently recruiting a transcriptional apparatus to nucleosomal DNA (Tang, Nogales 
et al. 2010). Among them, there is the SWI/SNF complex. The SWI/SNF family of 
chromatin remodeling complexes was initially discovered in yeast by two independent 
screenings aimed at identifying mutations in genes that affect the mating-type switching 
(SWI) and sucrose fermentation (Sucrose Non Fermenting - SNF) pathways. Chromatin 
remodeling complexes use the energy of ATP hydrolysis to slide the DNA around the 
nucleosome. The first step consists in the binding between the remodeler and the 
nucleosome. This binding occurs with nano molar affinity and reduces the digestion of 
nucleosomal DNA by nucleases. Upon ATP hydrolysis, the torsion subdomain carries 
out a directional DNA translocation. This event destroys histone-DNA contacts and 
creates a transient DNA loop that propagates around the nucleosome and resolves when 
it reaches the exit site on the other side of the nucleosome resulting in nucleosome 
repositioning. The tracking domain ensures that the waves of DNA loops can move only 
in one direction blocking any backward movement. The remodeler then resets its 
original position ready for a new remodeling cycle. 
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Figure 11. Schematic representation of the SWI/SNF dependent nucleosome remodeling process. 
During Step1, the translocase domain binds the nucleosome two turns away from the dyad. Upon ATP-
dependent hydrolysis, the torsion sub-domain generates a DNA loop that translocates through the tracking 
subdomain and the dyad, continuing in the second gyre (Step 2-3). The loop resolves when it reaches the 
exit site on the other side of the nucleosome (Step 4). The combination of these steps results in 
nucleosome repositioning. The complex is then ready for a new remodeling cycle (Step1). Adapted from 
(Tang, Nogales et al. 2010). 
 
1.2.2.1 Histone acetylation 
Histone acetylation occurs on lysine residues on H3 and H4 histone tails. It is the well-
studied histone modification. The mechanism for acetylation and deacetylation takes 
place on the NH3+ groups of Lysine amino acid residues. These residues are located on 
the tails of histones that make up the nucleosome of packaged dsDNA. The process is 
aided by factors known as Histone Acetyltransferases (HATs). HAT molecules facilitate 
the transfer of an acetyl group from a molecule of Acetyl Coenzyme-A (Acetyl-CoA) to 
the NH3+ group on Lysine. When a Lysine has to be deacetylated, factors known as 
Histone Deacetylases (HDACs) catalyze the removal of the acetyl group with a 
molecule of H2O. Acetylation has the effect of changing the overall charge of the 
histone tail from positive to neutral. Nucleosome formation is dependent on the positive 
charges of the H4 histones and the negative charge on the surface of H2A histone fold 
domains. Acetylation of the histone tails disrupts this association, leading to weaker 
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binding of the nucleosomal components. By doing this, the DNA is more accessible and 
leads to more transcription factors being able to reach the DNA. Thus, acetylation of 
histones is known to increase the expression of genes through transcription activation. 
Deacetylation performed by HDAC molecules has the opposite effect. By deacetylating 
the histone tails, the DNA becomes more tightly wrapped around the histone cores, 
making it harder for transcription factors to bind to the DNA. This leads to decreased 
levels of gene expression and is known as gene silencing (Verdone, Agricola et al. 
2006). Histone acetyl-transferases (HATs) are a protein family that mediate the 
acetylation of lysine residues on histone tails. The most important are CBP/p300, 
MYST family and GNAT family. Histone deacetylase (HDACs) mediate the opposite 
reaction, that is the removal of acetyl group from lysine residues on histone tails. 
HDACs are divided into 4 families. Class I includes HDAC1, 2, 3 and HDAC8. Class 
IIa includes HDAC 4, 5, 7 and 9, whereas Class IIb includes HDAC 6 and 10. HDAC 
Class III includes the Sirtuins and Class IV contains HDAC 11 (Gallinari, Di Marco et 
al. 2007).  
 Histone Acetyl-transferases (HATs) Histone deacetylases 
(HDACs) 
H3K9, K14, K18, 
K36 




p300, CBP HDAC3, class I HDACs,  
H4K5, K8, K12, 
K16, H3K14 
MYST family (Tip60, MOZ, HBO1) SIRT1, SIRT3 
H3K9, K14, K18 TFIIC, TAF1, HDAC1, SIRT1 
Table 4. Principal histone acetyltransferase (HATs) and deacetylases (HDACs) and their relative 
target. (Seto and Yoshida 2014).  
 
The most studied histone acetylation are acetylation of lysine 9, 14, 18 and 23 on H3 
tail and lysine 5, 8, 12 and 16 on H4 tail (Strahl and Allis 2000). Every of this signals 
correlate  with transcriptional activation. 
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1.2.2.2  Histone methylation 
Histone methylation consists in the addition of a methyl group to lysine or arginine 
residues. It preferentially occurs on histone H3 and H4 tails. Lysine and arginine 
residues both contain amino groups, which confer basic and hydrophobic 
characteristics. Lysine is able to be mono-, di-, or trimethylated with a methyl group 
replacing each hydrogen of its NH3+ group. With a free NH2 and NH2+ group, 
arginine can be mono-, di- or tri-methylated. Methylation is not studied as well as 
acetylation, because it‟s technically more difficult to detect (doesn‟t change the total 
charge of the histone). The majority of methylation occurs on lysine 4, 9 and 27 on H3 
tail. Histone methylation can be associated with either transcriptional repression or 
activation. For example, dimethylation and trimethylation of histone H3 at lysine 4 
(H3K4me3) is an active mark for transcription and is upregulated in hippocampus one 
hour after contextual fear conditioning in rats. However, dimethylation or trimethylation 
of histone H3 at lysine 9 (H3K9me2), a signal for transcriptional silencing, is increased 
after exposure to either the fear conditioning or a novel environment alone (Gupta, Kim 
et al. 2010).  
Histone methylation is mediated by enzymes that are specific for a single lysine or 
arginine residue. They catalyze the transfer of one, two, or three methyl groups to lysine 
and arginine residues of histoneproteins. Lysine methyltransferase can be divided into 
two groups: the ones which possess a SET domain (Su(var)3-9, Enhancer of Zeste, 
Trithorax), and the ones who don‟t have a SET domain. Both use S-adenosyl-
methionine as cofactor. There are two different types of protein arginine 
methyltransferases (PRMTs) and three types of methylation that can occur at arginine 
residues on histone tails. The first type of PRMTs (PRMT1,PRMT3,CARM1/PRMT4, 
and Rmt1/Hmt1) produces monomethyl arginine and asymmetric dimethyl arginine. 
The second type (JBP1/PRMT5) produces monomethyl or symmetric dimethyl arginine. 
The differences in the two types of PRMTs arise from restrictions in the arginine 
binding pocket (Branscombe, Frankel et al. 2001). 
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 Histone Methyltransferase (HMTs) Histone demethylase (HDMs) 
H3K4me1/2/4 SET1, MLL PHF8 
H3K9me3 Suv3-9H1/H2, SETDB1 KDM2B 
H3K27 EZH1, EZH2 KDM6 
Table 5. Principal histone methyltransferases (HMTs) and demetylase (HDMs) and their relative 
target (Khare, Habib et al. 2012) 
 
1.2.2.3  Histone phosphorylation 
Phosphorylation, particularly that of histones H1 and H3, has long been implicated in 
chromosome condensation during mitosis (Koshland and Strunnikov 1996). However, 
converging evidence suggests that H3 phosphorylation (specifically serine 10) is also 
directly correlated with the induction of immediate-early genes such as c-jun, c-fos and 
c-myc (Mahadevan, Willis et al. 1991). Histone phosphorylation can occur on serine, 
threonine and tyrosine residues and constitutes an essential part of the histone code. 
Phosphorylation of H2A(X) is an important histone modification that plays a major role 
in DNA damage response (Rossetto, Truman et al. 2010). A substantial number of 
phosphorylated histone residues are associated with gene expression. Interestingly, 
these are often related to regulation of proliferative genes. Phosphorylation of serines 10 
and 28 of H3 and serine 32 of H2B has been associated with regulation of epidermal 
growth factor (EGF)-responsive gene transcription. H3S10ph and H2BS32ph have been 
linked to the expression of proto-oncogenes such as c-fos, c-jun and c-myc (Lau, Lee et 
al. 2011). Indeed, in EGF-stimulated cells, phosphorylation of H3S10 is tightly coupled 
to H3 K9ac and K14ac, both marks of transcriptional activation. It has been shown that 
phosphorylation of H3S10 promotes acetylation of H3K14 by the Gcn5 
acetyltransferase in vitro and allows Gcn5-regulated gene transcription in vivo (Lo, 
Trievel et al. 2000). Phosphorylation is a chimeric modification, and its meaning 
depends on the chromatin conformation. It is interesting to observe that the same 
phosphorylation events can be implicated in multiple cellular processes involving 
chromatin modulation. The same phosphorylated residue can have significantly distinct 
effects on chromatin structure depending on the context in which it occurs. 
Phosphorylation of H3S10 and H3S28 is a good example of this duality: both 
phosphorylated residues are involved in chromatin condensation associated with mitosis 
and meiosis, as well as in chromatin relaxation linked to transcription activation. 
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1.2.3 DNA methylation 
 
DNA methylation is a process by which methyl groups are added to DNA. Methylation 
modifies the function of the DNA, altering its expression. When located in a gene 
promoter, DNA methylation typically acts to repress gene transcription. DNA 
methylation is essential for normal development and is associated with a number of key 
processes including genomic imprinting, X-chromosome inactivation, repression of 
repetitive elements, aging and carcinogenesis (Jin, Li et al. 2011). 
DNA methylation occurs at the cytosine bases of eukaryotic DNA, which are converted 
to 5-methylcytosine by DNA methyltransferase (DNMT) enzymes. The altered cytosine 
residues are usually immediately adjacent to a guanine nucleotide, resulting in two 
methylated cytosine residues sitting diagonally to each other on opposing DNA strands. 
The addition of methyl groups is controlled at several different levels in cells and is 
carried out by a family of enzymes called DNA methyltransferases (DNMTs). Three 
DNMTs (DNMT1, DNMT3a and DNMT3b) are required for establishment and 
maintenance of DNA methylation patterns. Two additional enzymes (DNMT2 and 
DNMT3L) may also have more specialized but related functions. DNMT1 appears to be 
responsible for the maintenance of established patterns of DNA methylation, while 
DNMT3a and 3b seem to mediate establishment of new or de novo DNA methylation 
patterns (Bestor 2000). Methylation can be directly observed by staining cells with an 
immunofluorescently labeled antibody for 5-methylcytosine. In mammals, methylation 
is found sparsely but globally, distributed in definite CpG sequences throughout the 
entire genome, with the exception of CpG islands, or certain stretches (approximately 1 
kilobase in length) where high CpG contents are found. In human DNA, 5-
methylcytosine is found in approximately 1.5% of genomic DNA, on the contrary, In 
embryonic stem (ES) cells, a substantial amount of 5-mC is also observed in non-CpG 
contexts (Lister, Pelizzola et al. 2009).  
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Figure 12. Methylation of cytosine residues in 5’-methyl cytosine happens thanks to DNA methyl 
transferases (DNMTs) which uses S-adenosylmethyonine as a cofactor.  
 
Although patterns of DNA methylation appear to be relatively stable in somatic cells, 
patterns of histone methylation can change rapidly during the course of the cell cycle. 
Despite this difference, several studies have indicated that DNA methylation and 
histone methylation at certain positions are connected. Indeed, evidence has been 
presented that in some organisms, such as Neurosporacrassa (Tamaru and Selker 2001) 
and Arabidopsis thaliana (Soppe, Jasencakova et al. 2002), H3-K9 methylation is 
required in order for DNA methylation to take place. Given the critical role of DNA 
methylation in gene expression and cell differentiation, it seems obvious that errors in 
methylation could give rise to a number of devastating consequences, including various 
diseases. Indeed, medical scientists are currently studying the connections between 
methylation abnormalities and diseases such as cancer, lupus, muscular dystrophy, and 
a range of birth defects that appear to be caused by defective imprinting mechanisms 
(Robertson 2005).  
DNA methylation can alter gene expression in two ways. First, the methylation of DNA 
itself may physically impede the binding of transcriptional proteins to the gene, and 
second, and likely more important, methylated DNA may be bound by proteins known 
as methyl-CpG-binding domain proteins (MBDs). MBD proteins then recruit additional 
proteins to the locus, such as histone deacetylases and other chromatin remodeling 
proteins that can modify histones, thereby forming compact, inactive chromatin, termed 
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heterochromatin. This link between DNA methylation and chromatin structure is very 
important. In particular, loss of methyl-CpG-binding protein 2(MeCP2) has been 
implicated in Rett syndrome; and methyl-CpG-binding domain protein 2 (MBD2) 
mediates the transcriptional silencing of hypermethylated genes in cancer (Soppe, 
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1.3 EPIGENETICS AND ALS 
 
Since epigenetic mechanisms were discovered and subsequently well described, a 
variety of physiological and pathological conditions were linked to alterations in the 
epigenetic regulation. Beyond the well-known epigenetic imprinting, that lead for 
example to Angelman and Prader-Willis disease (Knoll, Nicholls et al. 1989), several 
studies had clarified the connection between many human diseases and epigenetics. 
Among them, cancer and several neurodegenerative disorders had been linked to 
epigenetics alterations (Sharma, Kelly et al. 2010, Landgrave-Gomez, Mercado-Gomez 
et al. 2015). Addiction from abuse of drugs had been correlated to changes in normal 
epigenetic regulation (Renthal and Nestler 2008). 
ALS is one of the neurodegenerative diseases that has been linked to epigenetics. In the 
next paragraphs I will discuss what is known until now about this link. 
 
1.3.1 Acetylation and deacetylation of histonic and non histonic proteins 
 
1.3.1.1 Targets 
Beyond the most studied role of histone acetylation, lysine acetylation of non histonic 
proteins has emerged as a major covalent modification controlling diverse cellular 
processes and has been implicated in Alzheimer‟s disease (AD) and other 
neurodegenerative disorders. In particular, acetylation of misfolded tau proteins marks 
mature neurofibrillary tangles (NFTs) in AD and related tauopathies and represents a 
disease-specific marker of AD pathology (Cohen, Guo et al. 2011).  
A recent global proteomics study identified ~1750 proteins that are subject to lysine 
acetylation, including a distinct subset of RNA-binding proteins and associated factors 
(Choudhary, Kumar et al. 2009). Among them, the case of p53 is the well studied. 
Acetylation of p53 is important in regulating DNA damage response. The acetylation of 
p53 regulates its stability through crosstalk with the ubiquitination machinery, 
modulates interactions with TAF1, and regulates its transcriptional activity (Yang and 
Seto 2008).  
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Moreover, recent evidences demonstrated that TDP43 functions are regulated by 
acetylation. Cohen and colleagues demonstrated that TDP-43 acetylation impairs RNA 
binding and promotes accumulation of insoluble, hyper-phosphorylated TDP-43 species 
that largely resemble pathological inclusions in ALS and FTLD-TDP43 (Cohen, Hwang 
et al. 2015).  
1.3.1.2  Histone acetyltransferase 
Rouaux et al. observed that in a mouse model of ALS, it is present a severe decrease in 
the levels of histone acetyltransferase CBP (CREB-cAMP response element-binding 
protein-binding protein) (Rouaux, Jokic et al. 2003) in lumbar spinal cord motor 
neurons. Even if a decrease in H3 acetylation level was not revealed in the ALS mouse 
model, it was detected in cellular model of apoptosis. This imbalance induce a relative 
increase in global histone deacetylation, leading to the silencing of several anti-
apoptotic genes and the contemporary overexpression of pro-apoptotic ones (Saha and 
Pahan 2006). 
1.3.1.3  Histone deacetylases 
Several HDACs alterations have been linked to ALS. Among them, HDAC4 mRNA 
and protein greater levels in ALS patients have been linked to a severe phenotype a 
negatively correlates with re innervation processes (Bruneteau, Simonet et al. 2013). 
HDAC6 directly interacts with TDP43, and is deacetylated by it (Cohen, Hwang et al. 
2015), and, in association with FUS; regulates its mRNA (Kim, Shanware et al. 2010). 
Valle and colleagues reported the global deregulation of HDACs in two mouse models 
of ALS (Valle, Salvatori et al. 2014). Interestingly, they demonstrated that HDACs 
expression pattern changes from spinal cord to muscle.  
HDAC1 is a nuclear ubiquitous histone deacetylases class I of 55 kDa. It 
deacetylatesHDAC1 knockout embryos are lethal (Lagger, O'Carroll et al. 2002). 
Silencing of HDAC1 via RNAi lead to inhibition of proliferation associated with the 
upregulation of cyclin-dependent kinase (cdk) inhibitors. In addition, HDAC1 along 
with HDAC2 are recruited at the double stranded break sites and play an important role 
in DNA damage repair to promote non homologous end joining (NHEJ) (Miller, 
Tjeertes et al. 2010) . HDAC1 directly interacts with FUS in DNA damage sites (Wang, 
Pan et al. 2013). In my work, I demonstrated that HDAC1 interacts also with TDP43. 
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1.3.1.4  HDAC inhibitors and other ALS therapy approaches 
There are several evidences that restoring the correct acetylation/deacetylation balance 
using histone deacetylases inhibitors (HDACi) like Sodium Valproate (VPA), Sodium 
Butyrate (NaB) and Trichostatin A (TSA), contrasts MNs death and the 
neurodegenerative process (Sugai, Yamamoto et al. 2004). Anyway, their efficacy 
hasn‟t been proved in clinical yet. In my work, I tested the efficacy two HDACi, sodium 
4-phenylbutyrate and trichostatin A, in improving cell viability in a cellular model of 
ALS. 
 
Table 6.Principal HDAC inhibitors and their relative target. 
 
Sodium 4-phenylbutyrate (PBA) is an orally bioavailable, blood brain barrier (BBB) 
permeable, short-chain fatty acid that has been approved by the Food and Drug 
Administration (FDA) for treatment of urea cycle disorders. PBA has potential benefit 
for a wide variety of diseases like cancer, cystic fibrosis, thalassemia, spinal muscular 
atrophy as well as protein folding diseases such as type 2 diabetes mellitus, ALS and 
other neurodegenerative disesases. PBA and sodium valproate promoted motorneuron 
survival in mouse models of ALS, and compound efficacy was at least partially 
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attributed to the amelioration of abnormal histone hypoacetylation and transcriptional 
dysregulation, which is implicated in ALS (Ryu, Smith et al. 2005) (Rouaux, Panteleeva 
et al. 2007). Similarly, combined lithium and valproate treatment delayed disease onset, 
reduced neurological deficits and prolonged survival (Feng, Leng et al. 2008), and 
treatment with trichostatin A (Yoo and Ko 2011), or valproate (Sugai, Yamamoto et al. 
2004), delayed disease progression and/or increased survival in the SOD1-G93A mice. 
A phase II study in ALS individuals revealed that sodium phenylbutyrate was safe and 
tolerable, and histone acetylation was significantly increased after sodium 
phenylbutyrate administration (Cudkowicz, Andres et al. 2009). Conversely, a trial 
using valproic acid did not show a beneficial effect on survival or disease progression in 
patients with ALS (Piepers, Veldink et al. 2009). An open-label study, involving 40 
patients with ALS, has been performed to establish the safety and pharmacodynamics of 
escalating dosages of phenylbutyrate in 26 participants who completed a 20-week 
treatment phase. From this study emerges that phenylbutyrate is safe and the majority of 
subjects tolerated higher dosages (21 g/day) of this drug, but the lowest dose (9 g/day) 
was therapeutically efficient in improving histone acetylation levels. No deaths or 
clinically relevant laboratory changes occurred with phenylbutyrate treatment. Histone 
acetylation decreased by approximately 50% in blood buffy-coat specimens at screening 
and significantly increased after phenylbutyrate administration. In addition, blood levels 
of phenylbutyrate and the primary metabolite (PAA) increased with dosage (Piepers, 
Veldink et al. 2009). 
At present there is a clinical trials from Duke University (USA) recruiting patients to 
test the effect of Lunasin, a 43-amino acid polypeptide originally discovered in soy 
(ClinicalTrials.gov Identifier: NCT02709330). Lunasin can modify the epigenome and 
using an HAT assays, with acid-extracted histones as templates, it has been 
demonstrated that Lunasin specifically inhibited H4K8 acetylation while enhanced 
H4K16 acetylation catalyzed by HAT enzymes p300, PCAF, and HAT1A (Galvez, 
Huang et al. 2011). 
 
HDAC inhibition is not the only therapeutic strategy that is in course of study. 
Rodriguez-Paredes and colleagues reviewed all the molecules that have an effect in 
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Figure 13. A summary of all molecules targeting DNMTs, HMT, HDMs, SIRTs, HDACs and HATs. 
Adapted from (Rodriguez-Paredes and Esteller 2011) 
 
1.3.2 Methylation and demethylation 
 
Histone methylation of some particular residues is involved in the development of ALS. 
In particular, the trimethylation of lysine residues within histones H3 and H4 is a 
mechanism involved in reducing C9orf72 mRNA expression in expanded repeat carriers 
of c9FTD/ALS patients blood. The residues involved are lysine 9 and 27 on histone H3 
(H3K9, H3K27) (Belzil, Bauer et al. 2013).  
Recent evidences reported that FUS in methylated on a specific arginine residue. 
Arginine methylation modulates nuclear import of FUS via a TRN-binding epitope and 
chemical or genetic inhibition of arginine methylation restores TRN-mediated nuclear 
import of ALS-associated FUS mutants (Dormann, Madl et al. 2012). 
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1.3.3 Histone phosphorylation 
 
Very few data are available on histone phosphorylation and neurodegenerative 
mechanisms. Phosphorylation of histone H2AX on serine 139 is correlated to DNA 
damage response (Rogakou, Nieves-Neira et al. 2000) in a variety of conditions, such as 
in Alzheimer disease (Myung, Zhu et al. 2008). No any alterations in histone 
phosphorylation pattern has been demonstrated since now in ALS patients. 
Nevertheless, several evidences induce to speculate that histone phosphorylation may be 
involved in ALS pathogenesis, considering that DNA damage is one of the marker of 
ALS (Qiu, Lee et al. 2014).  
1.3.4 DNA methylation 
 
Another epigenetic hypothesis of ALS pathogenesis involves DNA methylation. Recent 
genome-wide analyses have found differential gene methylation in human ALS. 
Neuropathologic assessments have revealed that motor neurons in human ALS show 
significant abnormalities in Dnmt1, Dnmt3a, and 5-methylcytosine. Similar changes are 
seen in mice with motor neuron degeneration, and Dnmt3a was found abundantly at 
synapses and in mitochondria (Martin and Wong 2013). Furthermore, Chestnut and 
colleagues demonstrated that during apoptosis of cultured motor neuron-like cells, 
Dnmt1 and Dnmt3a protein levels increase, and 5-methylcytosine accumulates. In 
addition, enforced expression of Dnmt3a, but not Dnmt1, induces degeneration of 
cultured neurons (Chestnut, Chang et al. 2011). These data suggest that DNA 
methylation may be a therapeutic target in ALS. As a matter of fact, inhibition of Dnmt 
catalytic activity with small molecules RG108 and procainamide protects motor neurons 
from excessive DNA methylation and apoptosis in cell culture and in a mouse model of 
ALS (Chestnut, Chang et al. 2011).   
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Up to date, several experimental evidences underline the link between epigenetic and 
neurodegenerative diseases, such ALS. In particular, it is widely demonstrated that both 
in sporadic and in familiar ALS there is a severe decreasing in acetylation of N-terminal 
tail of histone H3 and H4. In parallel, many evidences suggest how there is a 
contemporary decreasing in the expression of histone-acetyl transferases such as CBP. 
Finally, in ALS patients several studies show an increase in DNA methylation. This 
data lead me to speculate on the role of ALS causative genes SOD1, FUS and TDP43 
on epigenetic deregulations. For this reason, I focused my PhD project on 3 main 
objectives: 
1) Understand the role of SOD1, FUS and TDP43 in regulating histone post-
translational modifications and the possible pathological implications. In this 
sense, I performed western blot analysis on cells lysates expressing SOD1, FUS 
or TDP43, with primary antibodies targeting histonic modifications linked to 
transcriptional activation or to transcriptional repression; in addition, we 
measured DNA methylation levels. 
2) Investigate the possible interaction between TDP43 and HDAC1. We performed 
co-immunoprecipitation experiments to evidence the interaction, the role of 
point pathological mutations and which is TDP43 interacting domain. 
3) Analyze the possible therapeutic effect of HDAC inhibitors such as Sodyum 
butyrate and Trichostatin A, performing cells vitality assays. 
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3. MATERIALS AND METHODS 
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Bacterial strain.  
Competent cells used are E. coli DH5-α. Bacterial cells are defective for the restriction 
and have mutations in relA1 and recA1 genes, to improve the stability and quality of 
recombinant plasmids.  
 
Cell lines.  
SH-SY5Y cell line: SH-SY5Y cells (ATCC, Rockville, MD, CRL-2266) are human cells 
derived from neuroblastoma cell line.  
Adeno-X 293 cell line: Adenovirus 5-transformed Human Embryonic Kidney 293 cell 
line (HEK 293; ATCC, Rockville, MD, CRL 1573) is used to package and propagate 
the recombinant adenoviral- based vectors produced with the BD Adeno-X Expression 
System.  
SH-SY5Y-HDAC1 cell line: SHSY-5Y cell line stably expressing HDAC1-FLAG 
created in our lab. Selection is maintained with 200 ug/ml of G1418.  
 
Adenoviral vectors.  







) were generated using the 
Adeno-X Expression System 1 (Clontech). Their production is completed in two stages. 
First, generation of mammalian expression cassette by cloning gene of interest into 
pShuttle2.Second, excision of expression cassette from pShuttle2 and insertion into I-
Ceu I and PI-Sce I sites of BD Adeno-X Viral DNA. All constructions were verified by 
automated sequencing.  
  
Plasmids and oligonucleotides. 
 










 Ampicillin 5x-myc 
pcDNA3-hHDAC1 hHDAC1 Ampicillin 1x-
FLAG 
pMTK-hTDP43-ΔN-term hTDP43-ΔN-term Ampicillin 5x-myc 
pMTK-hTDP43-ΔRRM1 hTDP43-ΔRRM1 Ampicillin 5x-myc 
pMTK-hTDP43-ΔRRM2 hTDP43-ΔRRM2 Ampicillin 5x-myc 
pMTK-hTDP43-ΔG-rich hTDP43-ΔG-rich Ampicillin 5x-myc 
pMTK-hTDP43-ΔRRM1/RRM2 hTDP43-ΔRRM1/RRM2 Ampicillin 5x-myc 
Table 7. Plasmids used in transfection experiments. 
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ΔN-term forw 5'-GAATTCAAGGCCTCTCGAGCCATAGTGTTGGGTCTCCCATGG-3' 
ΔN-term rev 5'-CCATGGGAGACCCAACACTATGGCTCGAGAGGCCTTGAATTC-3' 
ΔRRM1 forw 5'-CAGAAAACATCCGATTTAATAGTGCCTAATTCTAAGCAAAGC-3' 
ΔRRM1 rev 5'-GCTTTGCTTAGAATTAGGCACTATTAAATCGGATGTTTTCTG-3' 
ΔRRM2 forw 5'-GAGCCTTTGAGAAGCAGAAAACACAATAGCAATAGACAG-3' 
ΔRRM2 rev 5'-CTGTCTATTGCTATTGTGTTTTCTGCTTCTCAAAGGCTC-3' 
ΔG-rich forw 5'-CAGTTAGAAAGAAGTGGAAGAGGAATGTAGCTCGAG-3' 
ΔG-rich rev 5'-CTCGAGCTACATTCCTCTTCCACTTCTTTCTAACTG-3' 
ΔG-rich EcoRI forw 5'-ATTGAATTCTTTGGTGGTAATCCAGGTGGC-3' 














 were already 
present in the lab. Plasmid carrying hHDAC1 was bought from Addgene (#13820). 
TDP43 deletion mutants were made by site-directed mutagenesis protocol (Agilent 
Technologies Inc, Stratagene, QuikChange® Site-Directed Mutagenesis #200518). 
 
Antibodies.  
In the present study we used the following antibodies: mouse anti-myc (clone 9E10 
Sigma-Aldrich, 1:5000 for western blot and 1:10000 for immunofluorescence), rabbit 
anti-FLAG (Sigma Aldrich, F7452), rabbit anti-Cu/Zn SOD1 (Enzo Life Science, 
1:2000 final dilution), rabbit anti-TARDBP (Proteintech, 1:1500 final dilution), mouse 
anti-FUS/TLS (Santa Cruz Biotechnology, 1:1000 final dilution), mouse anti-β-actin 
(Sigma-Aldrich, 1:5000 final dilution), anti-phospho (Ser10)-acetyl (Lys14)-Histone H3 
(MilliporeMerck, 07-081,), anti-Histone H3 (diMethyl) (Lys4) (MilliporeMerck, 07-
030), anti-trimethyl Histone H3(Lys9) (MilliporeMerck, 05-1250), anti-Histone H3 
(MilliporeMerck,05-499), Alexa Fluor®488 goat anti-mouse IgG (Thermo Fisher 
Scientific), Alexa Fluor®647 goat anti-rabbit IgG (Thermo Fisher Scientific), Goat anti-
Mouse IgG Peroxidase conjugated (Millipore), Goat anti-Rabbit IgG Peroxidase 
conjugated (Millipore). 
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To inhibit HDAC1 activity, we used Sodium Butyrate (B5887, Sigma Aldrich) and 
Trichostatin A (T8552, Sigma Aldrich). Sodium Butyrate was weighted, solved in water 
at a stock concentration of 10 mM, and then diluted at the final concentration of 0,2 and 
0,04 mM. Trichostatin A was solved in ethanol, at the tock concentration of 1 mg/ml, 
and then diluted at the final concentration of 10 and 25 nM. 
Standard technique of molecular biology. 
All standard technique of molecular biology were performed according to Molecular 
Cloning–A Laboratory Manual (Sambrook, Russell et al. 2006). 
 
DNA purification from agarose gel. 
Whenever it was necessary to purify DNA from agarose gel was used the commercial 
Kit Wizard ® SV Gel and PCR Clean-Up System (Promega) according to the manual 
instructions.  
 
Mutagenesis and PCR reactions 
Site-directed mutagenesis was performed according to instruction manual (Agilent 
Technologies Inc, Stratagene#200518). PCR was performed using oligos indicated in 
table x. and PFU DNA Polymerase (Promega, M7741). The reactions were performed 
as follows: 
95 °C for 5‟  
95° C for 3‟ 
54-56 °C for 30‟‟              for 18 cycles 
72°C (1‟ for Kb) 
72° C for 10‟ 
PCR amplified DNA was DpnI digested (to disrupt non mutated DNA) and then 
transformed in competent DH5α cells. Positive clones were screened by sequencing. 
Alessandra Masala 
Epigenetic modifications associated with Amyotrophic Lateral Sclerosis (ALS) onset and progression 
PhD Thesis in Biomolecular and Biotechnological Sciences 





Plasmid DNA purification. 
When it has been requested a greater quality of plasmidic DNA (i.e. sequence analysis 
or cell's transfection), was used the commercial kit Wizard®Plus SV Minipreps DNA 
Purification System (Promega) and PureLink® HiPure Plasmid Midiprep Kit (Thermo 
Fisher Scientific) according to the manual instructions.  
 
Cell cultures.  
SH-SY5Y were cultured in Dulbecco MEM/F12 ground (Thermo Fisher Scientific), 
HEK293 in Dulbecco MEM (Thermo Fisher Scientific), always in the presence of 10% 
fetal calf serum, free of tetracycline contamination (Tet-free FCS, Clontech) and 
inactivated at 56 °C for 30‟. Medium contained100 units/ml penicillin G and 100 μg/ml 
streptomycin (Thermo Fisher Scientific). The cells were grown in an incubator at 37 °C 
in a humidified atmosphere containing 5% CO2. Trypsin (0.5 g/ml, 68 mM EDTA) was 
added to split cells, then diluted in fresh medium.  
 
Transfection of eukaryotic cells. 
Transient expression of each plasmid (1.5 μg DNA/5–7×105 cells) was obtained 
transfecting cells with lipofectamine LTX and PLUS reagent (Thermo Fisher 
Scientific). We diluted the optimized amount of plasmid DNA in OPTIMEM (Thermo 
Fisher Scientific) and then we added the optimized volume of PLUS™ Reagent directly 
to the diluted DNA. After mixing gently, we incubated for 5‟ at room temperature. 
Then, the optimized volume of Lipofectamine™ LTX was added directly to the diluted 
DNA, incubated for 30‟ at room temperature. DNA-lipid complexes are stable for 6 
hours at room temperature. DNA-lipid complex were added dropwise to the well 
containing cells. Medium was changed 4-6 hours later. 
Production of recombinant adenovirus. 
We plated HEK 293 cells at a density of 1–2 x 106 cells per 60-mm culture plate 12–24 
hours before transfection and incubated at 37°C in a humidified atmosphere maintained 
at 5% CO2. Each 60-mm culture plate was transfected with 5 μg of Pac I-digested BD 
Adeno-X DNA using standard transfection method. One day later, and periodically 
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thereafter, we check for cytopathic effect (CPE). One week later, cells were transferred 
to a sterile 15-ml conical centrifuge tube (without using trypsin: infected cells that still 
adhere to the bottom or sides of the culture plate can be dislodged into the medium by 
gentle agitation). We centrifuged the suspension at 1,500 x g for 5 min at room 
temperature. Pellets were resuspended in 500 μl sterile PBS. Cells were lysed with three 
consecutive freeze-thaw cycles: freeze cells in a dry ice/ethanol bath; cells were thawed 
by placing the tube in a 37°C water bath (do not allow the suspension to reach 37°C). 
and vortexed after each thaw. The lysate was transferred to a clean, sterile centrifuge 
tube and used immediately to infect a fresh 60-mm culture by adding 250 μl (50%) of 
the cell lysate directly to the medium, then incubated as normal. CPE was usually 
evident within one week. We repeated these steps two or three time until we reached a 
high titer viral preparation.  
 
Determination of adenoviral titer: End-Point dilution assay.  
Approximately 24 hours before beginning the titration protocol, we plate HEK 293 cells 
in two 96-well plates. We carefully seeded all wells at the same density (~10
4
 cells per 
well) in 100 μl of growth medium. Then, we prepare serial dilutions of your virus as 
follows:  
- 1:100 dilution by adding 10 μl virus stock to 990 μl sterile growth medium.  
- Starting with the 1:100 dilution, we prepared serial 1:10 dilutions by transferring 100 
μl diluted virus to 900 μl sterile growth medium.  
 




. We removed the 
96-well culture plate from the incubator and inspected the wells to ensure that the cells 
have attached to form an even monolayer. We added 100 μl diluted virus to each well in 
columns 1–10 and add 100 μl of virus-free growth medium to wells in columns 11–12, 
these wells serve as controls for the viability of non-infected cells. We incubated cells in 
a humidified CO2 (5%) incubator for 10 days at 37°C. Using a microscope, we checked 
each wells for cytopathic effect (CPE). For each row, we counted the number of wells 
having CPE. A well is scored as CPE positive even if only a few cells show cytopathic 
effects. We calculated the fraction of CPE-positive wells in each row. Finally, we 
calculated Viral Titer:  
- Titer (pfu/ml) = 10(x + 0.8)  
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x = the sum of the fractions of CPE-positive wells.  
The assay is a reliable indicator of viral titer only if the following three conditions are 
met: i) the negative control wells show no visible signs of CPE or growth inhibition; ii) 
wells infected with the least dilute virus (10
–3
) are all CPE-positive; iii) wells infected 
with the most dilute virus (10
–10
) are all CPE-negative.  
Adenoviral infection of eukaryotic target cells. 
We plated target cells (SH-SY5Y or SHSY-5Y-HDAC1) 12–24 hours before infection 
in the culture plates desired. The next day, we removed the growth medium and infected 
target cells diluting viruses at a multiplicity of between 5–30 pfu/cell in OPTIMEM 
(Thermo Fisher Scientific). We then incubated the cells in a humidified CO2 (5%) 
incubator at 37°C for 1 hour to allow the virus to infect the cells. Then, we added fresh 
complete growth medium and incubated in a humidified 5% CO2 at 37°C. We analyzed 
gene expression at different time points required and then we proceeded to further 
experimental manipulations. 
Assessment of cell viability. 
The viability of control SH-SY5Y cells or SH-SY5Y cells infected with adenoviruses 
encoding for fALS-causative genes was calculated after 72 hours through an MTS 
assay. Cell viability was assessed by a colorimetric assay using the 3(4,5-
dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium 
(MTS) assay (Cell Titer 96 Aqueous One Solution Assay, Promega), according to the 
manufacturer‟s instructions. Absorbance at 490 nm was measured in a multilabel 
counter (Victor X5, PerkinElmer). 
Immunofluorescence 
 
1×105 SH-SY5Y cells grown on a cover-glass were washed twice with PBS 1X and 
then fixed with 1 ml of 4% paraformaldehyde/PBS 1X for 10‟. Cells were 
permeabilized with 0.1% Triton X-100 in PBS and non-specific binding was blocked 
with 5% bovine serum albumin, 0.1% Triton X-100 diluted in PBS for 1 h at room 
temperature. Cells were incubated with primary antibodies diluted in blocking solution, 
overnight at 4°C and then with secondary antibodies and nuclear marker (TO-PRO3, 
Thermo Fisher Scientific or Hoechst 33342, Sigma-Aldrich), diluted in blocking 
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solution for 1 h at room temperature. Glasses were analyzed with a Leica TCS SP5 
confocal microscopy with LAS lite 170 image software. 
SDS-PAGE and western blot analysis 
Cells were lysed in Laemmli Buffer  (10% SDS, 50% glycerol, 25% 2-mercaptoethanol, 
0.02% bromophenol blue and 0.3125 M Tris HCl, pH approx. 6.8)- 10 ug of total 
extract were run on a SDS-PAGE 15% at 120 V in running buffer (25 mM Tris, 190 
mM glycine, 0,1% SDS), then protein were transferred on a nitrocellulose membrane, at 
186 mA, in transfer buffer (25 mM Tris, 190 mM glycine, 20% methanol). Membranes 
were incubated with primary antibodies dissolved in non-fat milk 3% in PBS-Tween 
0,05%, ON. Secondary antibodies conjugated to peroxidase were used at room 
temperature, for 1 hour. Peroxidase reactions were revealed by ECL solutions (Thermo 
Fisher).  
Analysis of modified-histone H3/total H3 ratio 
We acquired H3-modified signal, then we stripped the signal incubating with Glycine 
1M-ph 2,5. We re-incubated the membrane with total H3 antibody. We analyzed 
intensity of the signal using Gel Doc XR software. Intensity data of modified histone 
H3 and total histone H3 were used to calculate the ratio of modified histone and for the 




HEK-293 cells were plated on a 60mm dish. 24 hours later, cells were co-
trasnfected with pMTK TDP43
WT/M337V/A382T 
and pCDNA3-HDAC1. 48 hours after 
transfection, cells were collected in a 1,5 centrifuge tube and lysed in lysis buffer (NaCl 
150mM,Tris-HCl 20 mM pH 7,5, NP40 1%) with protease inhibitors 1:1000. Lisates 
were washed and centrifuged to discard pellet debris. Protein lisates were incubated 
with protein-A-sepharose for 30‟ in agitation at 4°C to pre-clear the lysates and reduce 
non-specific binding. Then, protein-A-sepharose was discarded andante-myc primary 
antibody 1:1000 was added. Lysates with anti-myc were incubated ON at 4°C in 
agitation. Then, new fresh protein-A-sepharose was added, to precipitate protein-
antibody complexes. The complexes were incubated for 2 hours at 4°C in agitation. 
Finally, the complexes were centrifuged, washed four times in lysis buffer, and then 
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protein-A-sepharose was lysed in Laemmli Buffer 1X to be processed in western blot 
analysis with anti-FLAG antibody. 
 
Cells viability assay with HDAC1 inhibitors 
2x10
4
 SHSY-5Y cells were plated on a 96 well dish 24 hours before infection. Cells 
were transduced as described above with adenoviruses carrying TDP43
WT/M337V/A382T
. 1 
hour after the transduction, cells were treated with NaB 0,2 or 0,04 mM or TSA 10 or 
25 nM. Treatment was repeated 24 hour after transduction. 48 hours after transduction, 
MTS assay was performed, as described above. 
Genomic DNA extraction 







 with a commercial kit (G1N70, Sigma 
Aldrich). 
P/ACE capillary electrophoresis 
To measure 5‟-methylcytosine amount in genomic DNA, we dried the samples (eluted 
in mqH2O) to lyophilize them. Then they were mixed with formic acid (100-μL final 
volume, 90% final concentration) and incubated at 130 °C for 80 min. After hydrolysis, 
the samples were exsiccated at 60 °C under a vacuum and the dry residue containing 
free bases was dissolved in 100 μL of acetonitrile/ water (50:50). Finally, they were 
stored at −20 °C or analyzed immediately. Capillary electrophoresis and next 
methylation analysis was performed by a PACE MDQ system according to Zinellu et al 
(Zinellu, Sotgia et al. 2011). 
Nuclear-cytoplasmic separation.  
1/2×10
6
 SH-SY5Y cells were transduced with TDP43 adenoviral vectors. 48 h after 
transduction cells were wash twice with cold PBS 1X, harvested in 500 μl of PBS 1X 
and centrifuged at 1000 x g for 3 min at 4 °C. The pellet were resuspended gently in 500 
μl of S1 buffer (10mM Hepes pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.1mM EGTA pH 
7.0, 1M DTT (1 μl/2ml), and protease inhibitors mixture, Sigma-Aldrich). We syringed 
ten times at 4 °C and centrifuge at 1000 x g for 3‟ at 4 °C, supernatant (cytoplasmic 
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fraction) was collected and the pellet was resuspended gently in 500 μl of S1 buffer. We 
centrifuged at 3000 rpm for 3‟ at 4 °C, the pellet was resuspended with 30μl of S2 
(10mM Hepes pH 7.9, o.4M NaCl, 1.5mM MgCl2, 0.1mM EGTA pH 7.0, 5% glycerol 
1M DTT (1 μl/2ml), and protease inhibitors mixture, Sigma-Aldrich). We shaked for 30 
min at 4 °C, centrifuge for 10 min at 4 °C at 12,000xg and collected the supernatant 
(nuclear fraction).  
HDAC1 enzymatic assay 
HDAC1 activity was measured with a commercial kit (Epiquik HDAC1 assay kit 
(colorimetric), Epigentek, P-4005-96). We first plated 2x10
6
 SHSY-5Y cells, 
transduced them, and 48 hours later we purified the nuclear fraction. On 5 ug of protein 
from the nuclear extract, according to manufacturer‟s instructions, we performed the 
assay. Colorimetric results were read on a multiplate reader. 
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4.1 ANIMAL AND CELLULAR MODELS FOR ALS 
In order to study epigenetic modifications induced by the expression of 3 
differentALScausative-gene,SOD1 (OMIM # 105400), TDP43 (OMIM # 612069) and 
FUS (OMIM # 608030), we decided to use the following cellular and animal models 
able to mimic the genetic alterations that cause ALS: 
(i) Transgenic mice SOD1-G93A. Different transgenic mice bearing mutations on 
the sod1 gene have been developed as ALS models, among which there is the G93A 
mouse strain. These mice die within about 140 days, presenting typical ALS symptoms: 
motoneuronal death, muscular atrophy, and paralysis. 
(ii)  Adenoviral delivery of ALS causative-gene Although cell lines over-expressing mutant 
SOD1 have been widely used as model of ALS, it is well known that stable cell lines tend to 
show adaptive effects towards toxic genes. In order to prevent it we plan to obtain high level of 
expression using an adenoviral delivery strategy, one of the most reliable methods for 
introducing genes in mammalian transformed cell lines as well as into primary culture.In 
particular, both WT and mutant variants of the mentioned genes were expressed. 
Table 9.Familiar ALS causative genes and relative pathological mutations. 
 
To drive the expression of ALS-causative genes, the recombinant adenoviruses 
encoding for hSOD1, hTDP43 (WT or mutant) and hFUS (WT or mutant) genes were 
produced. Recombinant adenoviruses provide a versatile system for gene expression 
studies and therapeutic applications. Since infection by adenovirus is not cell-cycle 
dependent, it is possible to deliver the gene of interest to primary as well as to 
transformed cell lines. Following infection, target gene was transiently expressed at 
high levels since many cells received multiple copies of the recombinant genome. 
Expression is transient because adenoviral DNA normally does not integrate into the 
cellular genome. The assembly of recombinant adenoviruses is completed in few stages: 
first the cDNA coding for WT or pathological mutant SOD1, TDP43 and FUS was 
fALS OMIM  Gene  Pathological mutations 
ALS1  # 105400  SOD1  G93A, H80R  
ALS6  # 608030  FUS  R495X, R521G, P525L  
ALS10  # 612069  TDP43  M337V, A382T  
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cloned into pShuttle2 vector (in fusion with five repeats of myc epitope 5xMyc for 
TDP43 and FUS). Then, the expression cassette was excised from recombinant 
pShuttle2 plasmid DNA by digesting with the homing endonucleses I-Ceu I and PI-Sce 
I and ligated into Adeno-X Viral DNA. Recombinants were selected with kanamycin 
and screened by restriction endonuclease digestion. Third, the recombinant adenoviral 
construct was cleaved with PacI to expose its inverted terminal repeats and transfected 
into a packaging cell line Adeno-X 293. After 7–10 days, viruses were harvested and 
amplified by infecting packaging cells for three times to obtain high titer virus stock. By 
performing an end-point dilution assay, the final yields were evaluated generally around 
10
8 
plaque-forming particles per ml. Recombinant adenoviruses were finally used to 
infect neuronal SH-SY5Y with a multiplicity of infection (M.O.I.) of 5-30 pfu/cell. At 
the indicated time after infection cells were harvested and protein extracts analyzed by 
western blot.  
4.1.1 Characterization of ALS cellular models 
 
As an initial step to characterize the effects of adenoviral delivery of fALS genes into 
neuronal cells we evaluated metabolism of SH-SY5Y cells after infection with scalar 
concentration of infectious adenoviruses encoding for WT or mutant fALS genes 
through western blot analysis on total lysates. The cellular viability was analyzed 
performing a viability assay using a commercial kit (CellTiter 96® AQueous One 
Solution Cell Proliferation Assay, Promega). Neuronal SH-SY5Y cells were infected 
with increasing concentrations of adenoviruses encoding for WT or mutant fALS genes 
and 72 hours post-infection the MTS assay was performed, according to the manual 
instruction. As expected, SOD1, both WT and mutant forms, doesn‟t induce any 
decrease in cells vitality, except for the infection with 30 pfu/cell, where the toxic effect 
could be due to the infection itself and not to the over expression of the SOD1 gene. 
Concerning FUS, we saw a mild decrease in cells vitality, for WT, R521G and R495X 
forms. TDP43 is extremely toxic, reducing cells vitality of the 20%, both in WT and 
mutant forms (see figure 14). 
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Figure 14.ALS causative genes SOD1, FUS and TDP43 overexpression alter cells viability. A) MTS 
assay on SHSY-5Y cells transduced by SOD1 adenoviruses, at a final concentration of 5, 15 and 30 
PFU/cell. B) MTS assay on SHSY-5Y cells transduced by FUS adenoviruses, at a final concentration of 
5, 10 and 30 PFU/cell. C) MTS assay on SHSY-5Y cells transduced by TDP43 adenoviruses, at a final 
concentration of 5, 15 and 30 PFU/cell. 
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4.2 ANALYSIS OF HISTONE POST-TRANSLATIONAL MODIFICATIONS 
H3-K14ac-S10ph, H3K14me2 AND H3K9me3 
 
As stated in general introduction (paragraph 3) in both ALS experimental models and 
patients, a general misregulation of the epigenome had been observed (Rouaux, Jokic et 
al. 2003, Paez-Colasante, Figueroa-Romero et al. 2015). In order to evaluate if ALS 
causing genes SOD1, FUS and TDP43 toxicity could be linked to alterations in the 
epigenetic machinery, we analyzed some histone post-translational modification linked 
to: 
1. transcriptional activation:  
- dimethylation of lysine 4 on H3 tail (H3-K14me2), that is associated to active 
transcription and splicing (H3K4 trimethylation could facilitate pre-mRNA 
maturation via bridging of the spliceosomal components to actively transcribed 
gene). 
- phospho-acetylation of serine 10 and lysine 14 on H3 tail (H3-K14ac-S10ph is 
associated to transcriptional activation of immediate early-genes in neuronal 
populations in response to a variety of stimuli); 
2. transcriptional repression: trimethylation of lysine 9 on H3 tail leads to 
transcriptional repression (H3-K9me3). 
We tested, in a preliminary experiment, some histone modifications (H3-K14ac-S10ph 
and H3K4me2) in cells under oxidative stress conditions, which is considered one of the 
most important causes of death of motor neurons in ALS. SHSY-5Y cells were treated 
with scalar concentrations of H2O2 and analyzed 30‟ and 3 h later. Equal amount of total 
protein lysates were separated by SDS-PAGE and epigenetic markers aforementioned 
were analyzed by western blot analysis. As shown in figure 15, H3-K14ac-S10ph is 
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strongly reduced, according to what mentioned by Rouax et al, 2007. H3K4me2 levels 
do not show any significant variation.  
 
Figure15: Western blot analysis on 10 ug of proteic extracts of SHSY-5Y cells treated at different 
times with scalar concentrations of H2O2. From the left: control cells, 30‟ treatment with H2O2 300 uM, 
3h with H2O2 300 uM, 30 „ with H2O2 600 uM, 3h with H2O2 600 uM, 30‟ with H2O2 1 mM, 3h with H2O2 
1 mM. 
 
We then decided to transduce SHSY-5Y with adenovirus coding for WT or mutant 
SOD1, FUS and TDP43 and 48 hours later total cell lysates were analyzed by western 
blot. 
 
4.2.1 SOD1 induce an in vitro decrease in transcriptional activation markers 
and an increase in repression markers 
 
As shown in figure 17, expression of SOD1 pathological mutants G93A and H80R 
induce a significant decrease in transcriptional activation markers H3-S10Ph-K14Ac 
and H3-K14me2 (p<0,05). Nevertheless, SOD1 WT overexpression induces an increase 
in transcriptional repression marker H3-K9me3. A similar effect is not observed in 
pathological mutant forms. Data on histone modification levels were normalized by 
total/ modified H3 ratio. 
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4.2.2 SOD1 reduction of H3-14Ac-S10Ph marker is in proportion with the time 
of infection 
 
We then, performed a time-course experiment, analyzing H3K14acS10ph marker at 24, 
48 and 72 hours form transduction with SOD1
WT/G93A/H80R
. We observed that the 
reduction in the marker is in proportion with the increasing in transduced SOD1 
expression, which accumulates over time (see figure 16). Results are similar to what 
observed above, i.e. that point pathological mutations of SOD1 gene lead to a reduction 
in transcriptional activation marker H3-K14ac-S10ph levels. 
 
Figure16. Increasing expression in time with SOD1 correlates with the decrease of H3-K14acS10ph 
marker level. SHSY-5Y cells were transduced with SOD1
WT/G93A/H80R
 and expression level of H3-
K14acS10ph marker were analyzed by western blot with 10ug of total extract form cells at 24 h, 48 h or 
72 h after transduction. 
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Figure17. Pathological point mutation in SOD1 induce a decrease in transcriptional activation 
markers whereas SOD1
WT
 induce an increase in transcriptional activation marker. SHSY-5Y cells 
were transduced with 10 PFU/cell of SOD1
WT/G93A/H80R
 adenoviral vectors. Total extract were collected 48 
h later. SDS-PAGE and western blot analysis were performed according to Materials and Methods. From 
the top: expression of SOD1
G93A/H80R
 induce a decrease in transcriptional activation markers H3-
K14acS10ph and H-K14me2. Overexpression of SOD1
WT 
induce an increase in transcriptional activation 
marker H3-K9me3. Data were analyzed by ONE-WAY ANOVA with a level of significance of 0.05.  
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4.2.3 SOD1 induce a decrease in transcriptional activation markers in SOD1 
G93A spinal cord mice 
 
We demonstrated that H3-K14Ac-S10-Ph and H3-K14me2 transcriptional activation 
signal are reduced in motor neurons spinal cord of SOD1
G93A
 mice when compared to 
non transgenic mice (see figure 18). Spinal cords were collected from non-
symptomatic(70 days from birth),pre-symptomatic (100 days from birth) and 
symptomatic mice (140 days from birth) SOD1
G93A
mice. Non transgenic littermates 
were used as controls. As shown in 18, we performed an hematoxylin and eosin stain to 
mark motor neurons death areas. In non-transgenic mice, motor neurons are evident, on 
the contrary, transgenic SOD1
G93A
 spinal cord shows a significant reduction in motor 
neurons, both in the pre-symptomatic (100 days after birth) as in the symptomatic mice 
(140 days after death), where motor neuronal death is almost complete. 
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Figure 18 Ematoxylin-eosin stain of 10 um slides of nTg 100 days mice (A), or Tg SOD1
G93A
 in pre 
symptomatic form (B) or at 140 days after birth, simptomatic form (C). 
 
Then, we performed immunofluorescence analysis on spinal cord slides collected from 
the same mice. We used monoclonal antibody directed against H3-K14Ac-S10ph and 
against SMI-32, a specific marker of neurofilaments to stain neurons. Confocal 
microscopy allowed us to evidence a reduction in H3K14Ac-S10ph levels in motor 
neurons of SOD1
G93A
presymptomatic and moreover of symptomatic mice, compared to 
control non-transgenic mice. H3K4me2 levels too decrease in transgenic mice 
compared to control non-transgenic mice, even if the reduction is less intense (figure 
19).  These in vivo evidences confirm what observed in in vitro experiments, i.e. that 
SOD1
G93A
 induce a decrease in histonic markers associated with transcriptional 
activation. 
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Figure 19. Immunofluorescence analysis on spinal cord sections SOD1
G93A
 demonstrated that 
SOD1
G93a 
induce a significant decrease in transcriptional activation markers. A) of SOD1
G93A
 mice, 
pre symptomatic at 100 days, and symptomatic, at 140 days. White arrows indicates that H3-PhAC signal 
is drastically reduced in both cases compared to control wild type mice. B) H3K4me2 signal is reduced in 
pre symptomatic and symptomatic mice compared to wild type control mice (white arrows). 
Alessandra Masala 
Epigenetic modifications associated with Amyotrophic Lateral Sclerosis (ALS) onset and progression 
PhD Thesis in Biomolecular and Biotechnological Sciences 
University of Sassari 
 64 
4.2.4 FUS and TDP43 overexpression induce an increase in transcriptional 
repression marker 
 
As for SOD1, different lines on evidenced linked FUS and TDP43 to alteration in gene 
expression, that can be linked to directly or indirectly to alteration in epigenetic 
markers. We thus decided to test if also FUS or TDP43 pathological mutants can 
globally influence histone modifications. As shown in figure 20, both WT or 
pathological mutants FUS or TDP43 overexpression doesn‟t induce a similar effect 
compared to SOD1,since we do not observe a decrease in transcriptional activation 
markers. Moreover, we could observe any statistically significant increase in 
transcriptional repression marker H3-K9me3 in cells expressing SOD1
WT
but not mutant 




, even if in these 
cases the data are not statistically significant. (see figures 20, 21). 
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Figure 20. Pathological point mutation in TDP43 doesn’t alter transcriptional activation markers 
whereas TDP43
WT
 induce an increase in transcriptional activation marker. SHSY-5Y cells were 
transduced with 10 PFU/cell of TDP43
WT/M337V/A382T
 adenoviral vectors. Total extract were collected 48 h 
later. SDS-PAGE and western blot analysis were performed according to Materials and Methods. From 
the top: expression of TDP43
M337V/A382Tdoesn‟t induce any decrease in transcriptional activation markers 
H3-K14acS10ph and H-K14me2. Overexpression of TDP43
WT 
induce an increase in transcriptional 
activation marker H3-K9me3. Data were analyzed by ONE-WAY ANOVA with a level of significance of 
0.05.  
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Figure 21. Pathological point mutation in FUS doesn’t alter transcriptional activation markers 
whereas FUS
WT
 induce an increase in transcriptional activation marker. SHSY-5Y cells were 
transduced with 10 PFU/cell of FUS
W/R521G/P525L/R495X
 adenoviral vectors. Total extract were collected 48 h 
later. SDS-PAGE and western blot analysis were performed according to Materials and Methods. From 
the top: expression of FUS
R521G/P525L/R495X
 doesn‟t induce any decrease in transcriptional activation 
markers H3-K14acS10ph and H-K14me2. Overexpression of FUS
WT 
induce an increase in transcriptional 
activation marker H3-K9me3. Data were analyzed by ONE-WAY ANOVA with a level of significance of 
0.05.   
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4.3 SOD1G93A OVER EXPRESSION INDUCES A GLOBAL INCREASE IN 
DNA METHYLATION  
 
Several evidences shows that 5-methylcytosine increase in ALS patients (Martin and 
Wong 2013). To further understand the possible role of WT or pathological mutant 
SOD1, FUS or TDP43, we analyzed global DNA methylation levels by a HPLC-P/ACE 
approach. We purified genomic DNA from cells transduced by adenoviral particles, and 
we analyzed 2,5 ug, as described in Materials and methods. Data were analyzed by 
Graph Pad software, in a ONE-WAY ANOVA. Again, SOD1 pathological mutant 
G93A induces a significant increase in 5-met-cyt (figure 22). No significant alterations 




 induce a significant increase in global DNA methylation. SHSY-5Y cells were 
transduced with 10 PFU/cell of SOD1 adenoviral vectors. Genomic DNA were extracted with a 
commercial kit (See Materials and Methods). Levels of 5mCyt were quantified with a F/ACE approach. 
ONE-WAY ANOVA followed by Bonferroni test evidenced a statistically significant increase in 5mCyt 
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 interacts with HDAC1 in vitro 
 
Histone deacetylases is a complex class of proteins involved in the regulation of the 
epigenome, linked to ALS onset and progression, at many different levels: (i) class III 
histone deacetylases SIRT1 decreases in the spinal cord, but increases in muscle during 
the progression of the disease, while SIRT2 mRNA expression increases in the spinal 
cord in both G93A-SOD1 and G86R-SOD1 mice but protein expression is substantially 
unchanged in all the models examined (Valle, Salvatori et al. 2014);(ii) treatment with 
HDAC inhibitors phenylbutyrate and sodium valproate promoted motor neuron survival 
in mouse models of ALS (Kazantsev and Thompson 2008); (iii) FUS interacts with 
HDAC1 by its G-rich and C-terminal domains (Wang, Pan et al. 2013); (iv) TDP43 is 
deacetylated by HDCA6 (Cohen, Hwang et al. 2015).  We thus decided to perform co-
immunoprecipitation experiments between TDP43 and three different HDCAs, namely 
HDAC1, HDAC6 and SIRT1, expressed in frame with a FLAG epitope (figure 23). 
Despite numerous assays we were not able to express at high levels neither HDAC6 or 
SIRT1 (figure 23), and in the co-ip experiment we were not able to detect a positive 
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Figure 23. Histone deacetylase 1, 6 and Sirtuin 1 are the major representative of HDAC families. A) 
Agarose gel analysis of pCDNA3-HDAC1-FLAG, pCDNA3-HDAC6-FLAG and pECE-SIRT1-FLAG 
plasmids. B) Anti-FLAG western blot analysis on protein total extract from SHSY-5Y cells transfected 
with 500 ug of plasmids above. 
 
Figure 24. TDP43 doesn’t interact with HDAC6 or SIRT1. HEK 293T cells were transiently co-
transfected with FLAG-tagged HDAC6 (FLAG-HDAC6) or FLAG-tagged SIRT1 (FLAG-SIRT1). 48 
hours after transfection, total cell lysates were subjected to immunoprecipitation with anti-c-myc 
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We thus focalized our attention on HDAC1. We transfected FUS or TDP43 fused with 
myc-tag in association with HDAC1 fused with FLAG-tag. We immunoprecipitated the 
protein lysates with an anti-myc monoclonal antibody and we revealed the interaction 
by western blot analysis with a anti-FLAG monoclonal antibody. We confirmed the 
interaction between FUS and HDAC1, and we observed that also TDP43
WT
 interacts 
with HDAC1 (fig. 25).  
 
Figure 25. TDP43 interacts with HDAC1. HEK 293T cells were transiently co-transfected with FLAG-
tagged HDAC1 (FLAG-HDAC1), (A) c-myc-tagged FUS (myc-FUS) or c-myc-tagged TDP43 (myc-
TDP43) (B) 48 hours after transfection, total cell lysates were subjected to immunoprecipitation with anti-
c-myc monoclonal antibody 9E10. Binding of HDAC1 to TDP43 was analyzed with western blotting 
with the indicated antibody. 




interact with HDAC1 in vitro 
 
Unlike wild-type (WT) TDP43, pathogenic TDP43 mutants are mislocalized in the 
cytoplasm. Therefore, to determine whether the binding of HDAC1 to pathogenic 
mutant HDAC1 is altered, we used WT TDP43 and pathogenic TDP43 variants 





 interact with HDAC1 and we found 
no significant difference in HDAC1 binding affinity between mutants and WT TDP43, 
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while, at least in our experimental paradigms, TDP43/HDAC1 interaction seems to be 
stronger than the one with FUS (figure 26). 
 
Figure 26.TDP43 interacts with HDAC1. HEK 293T cells were transiently transfected with myc-
taggedTDP43 WT or mutant expression constructs (M337V or A382T) and FLAG-taggedHDCA1. Co-
immunoprecipitation was performed as shown in figure 25.B. Bar graph shows the relative binding of 
HDAC1 to mutantTDP43, normalized to TDP43 WT. The data were obtained from four independent 
experiments; n.s .indicates p > 0.05 versus WT binding, analyzed with one-way ANOVA. 
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4.4.3 HDAC1 localizes in the nucleus and partly co-localizes with TDP43 
 
Axonal damage described in brains of humans with multiple sclerosis and of mice with 
cuprizone-induced demyelization, has been associated with HDAC1 nuclear export, a 
critical event for impaired mitochondrial transport (Kim, Shanware et al. 2010). To 
investigate if mutant TDP43 expression can affect HDCA1 localization we decided to 
use different experimental approach. First of all we produce a stable SHSY-5Y cell line 
stably expressing HDAC1 fused in frame with FLAG tag. Single clones were isolated 
and tested for HDAC1 expression by western blot and confocal microscopy (Figure 27). 
FLAG-positive selected clones were clone 8, clone 9 and clone 10. 
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Figure 27. Western blot and immunofluorescence analysis on screened clones of SHSY-5Y cells 
stably expressing HDAC1-FLAG. Clone 11 were used as a negative control. HDAC1 was revealed with 
anti-FLAG monoclonal antibody; β-actin was used as a control for the cytoplasm.  
We then look at HDCA1 localization in 3 different cellular models: 
- SHSY-5Y-HDCA1 (clone 8 and 10) and SHSY5Y transduced with WT or 
pathological mutant TDP43 
- SHSY-5Y co-transfected with HDAC1 and with WT or pathological mutant 
TDP43. 
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As show in figure 28 in all the experimental condition tested, HDAC1 retains its 
nuclear localization (Data shown refers only to HDAC1-clone 10 transfected with 
wild type or pathological mutants TDP43, figure 28). 
 
Figure 28. HDAC1 is localized in the nucleus also in presence of TDP43 pathological mutants. 







and pCDNA3-HDAC1. TDP43 signal was revealed by anti-myc primary antibody and secondary anti-
mouse-ALEXA 488, HDAC1 was revealed by anti-FLAG antibody and secondary anti-rabbit ALEXA 
647. Slides were analyzed by Leica confocal microscope.  
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4.4.4 Development of TDP43 deletion mutants  
 
For determining which TDP43 functional domain interacts with HDAC1, we produced 
deletion mutants of TDP43 lacking of one or two protein domain (See fig. 29).We 
designed couples of deletion oligos  (see Materials and Methods, table 7) and we 
performed site-directed mutagenesis according to Agilent Quick-change II manual. 
After PCR, DNA was DpnI-digested and transformed into DH5α. DNA was extracted 
from positive colonies, sequenced and amplified. We created deletion mutants for every 
functional domain, i.e. TDP43 lacking N-terminal domain, RRM1 domain, RRM2 
domain or glycine-rich domain; finally, we developed the double-mutant lacking both 
RRM1 and RRM2 domain (see picture 29). DNA plasmids were then transfected into 
SHSY-5Y and SHSY-5Y-HDAC1 cells to be characterized. By western blot analysis, 
we confirmed protein dimension.  
 
Figure 29. TDP43 deletion mutants lacking one or two protein domain. By in situ directed 
mutagenesis we produced 5 TDP43 deletion mutants, named TDP43-ΔN-term, TDP43-ΔRRM1, TDP43-
ΔRRM2, TDP43-ΔGrich, TDP43-ΔRRM1/RRM2.Western blot analysis with anti-myc antibody 
confirmed the expected size of the mutant proteins.  
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Immunofluorescence analysis demonstrates that also deletion mutants localizes in the 
nucleus, except for TDP43-N-term, that lacks NLS signal and is particularly unstable 
(figure 30). 
 
Figure 30. Immunofluorescence analysis of TDP43 deletion mutants, in SHSY-5Y cells and in a 
stable cell line SHSY-5Y-HDAC1.The top line shows SHSY-5Y cells expressing TDP43 deletion 
mutants and their localization. The bottom line shows TDP43 deletion mutants expressed in SHSY-5Y-
HDAC1 clone 10.  
 
4.4.5 RRM1 and RRM2 domains are both necessary to mediate TDP43-HDAC1 
interaction 
 
For determining which TDP43 domain interacts with HDAC1, the myc-tagged TDP43 
fragments, previously described, were co-immunoprecipitated with FLAG-tagged 
HDAC1 in HEK 293T cells. We didn‟t test the N-terminal domain deletion mutant due 
to its completely citoplasmatic localization. We found that full-length HDAC1 strongly 
interacts with G-rich, while the interaction is reduced when one of the two RRM 
domains is missing and abolished only when both RRM1 and RRM2 are deleted. This 
result showed that HDAC1 physically interacts with TDP43 through the RRM1 and 
RRM2 region of TDP43 (figure 31). 
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Figure 31.Coimmunoprecipitation between TDP43 deletion mutants and HDAC1. A) HEK 293T 
cells were transiently transfected with myc-tagged TDP43 WT or deletion mutants expression constructs 
(ΔRRM1, ΔRRM2, ΔG-rich, ΔRRM1/RRM2) and FLAG-taggedHDCA1. Co-immunoprecipitation was 
performed as shown in figure 25 .B) Bar graph shows the relative binding of HDAC1 to mutantTDP43, 
normalized to TDP43 WT. The data were obtained from four independent experiments; n.s.indicates p > 
0.05 versus WT binding, analyzed with one-way ANOVA. 
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4.5 TDP43 DOESN’T ALTER HDAC1 ACTIVITY IN VITRO 
 
In order to better understand the possible physiological link between TDP43 and 
HDAC1, we performed enzymatic assay based on a commercial kit (see materials and 
methods), to test HDAC1 activity. We transduced SHSY-5Y and SHSY-5Y-HDAC1 
cells with adenoviral particle coding for WT or pathological mutant TDP43, and 48h 
later we performed, according to manufacturer‟s instructions, a colorimetric assay to 
detect HDAC1 activity. We observed that, in both cell lines, TDP43
WT
 seems to reduce 
HDAC1 activity, comparing that to cells expressing mutant forms TDP43
M337V/A382T
. 
Anyway, no any significant difference was observed (see figure 32). 
 
Figure 32.Wild-type or pathological mutant of TDP43 overexpression doesn’t alter HDAC1 activity 
in vitro. SHSY-5Y or SHSY-5Y-HDAC1 cells were transduced with adenoviral vectors carrying TDP43 
WT and mutant forms (M337V or A382T), or with an empty adenovirus, as a control. 5 ug of nuclear 
extracts was processed with a commercial kit as indicated in Materials and Methods. HDAC1 enzymatic 
activity was indirectly calculated from the colorimetric level measured by a multi-plate reader. ONE-
WAY ANOVA doesn‟t indicate any significant difference (p>0,05).  
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4.6 TDP43 AND HDAC1 HAVE A SYNERGIC EFFECT IN DECREASING 
CELLS VITALITY 
 
To enlighten the possible functional role of HDAC1 in TDP43 pathway, we performed 
MTS vitality assay in cells expressing or not HDAC1, in a transient or stable way. First 







, and we measured cellular vitality in presence or in absence of HDAC1, 
expressed transfecting pCDNA3-HDAC1 (figure 33, table A). We observed a mild, not 





 and HDAC1. Even if we couldn‟t demonstrate a statistically significant 
difference, we observed this trend several times. In order to evaluate if HDAC1 way of 
expression could interfere with our results, we designed a similar experiment, but 
transducing TDP43 in SHSY-5Y cells or in the stable cell line SHSY-5Y-HDAC1 




toxicity is worsened by 
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Figure 33. TDP43 and HDAC1 have a synergic effect in promoting cell toxicity. A) SHSY-5Y cells 
were transfected with plasmids carrying TDP43 WT or pathological mutants (M337V or A382T) and 
were transfected (black bars) or not trasnfected (white bars)  with plasmids carrying HDAC1 gene. 
TDP43 confirms its toxicity, and so does HDAC1. Black arrows indicates cells in with the co-expression 
of the two proteins induce a worsening in cell viability. B) HSY-5Y (white bars) or SHSY-5y-HDAC1 
cells (black bars)  were transfected with plasmids carrying TDP43 WT or pathological mutants (M337V 
or A382T). Black arrows indicates cells in which the co-expression of TDP43 and HDAC1 induce a 
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4.6.1 Possible therapeutic effect of HDAC inhibitors  
 
HDAC inhibitors (HDACi) Sodium butyrate (NaB) and Trichostatin A (TSA) are 
known to have several therapeutic effect in epigenetic correlated pathologies, like 
cancer, neurological disease, immune disorders, and also in ALS (Petri, Kiaei et al. 
2006, Falkenberg and Johnstone 2014). One of the reasons why we investigated on the 
possible therapeutic role of HDACi is that ALS is characterized by a severe histone 
deacetylation. In this part of our study, we tested the effect of two of these inhibitors, 
NaB and TSA in our ALS TDP43-related cellular model. As described in Materials and 






 in SHSY-5Y cells, we 
treated cells and we analyzed if HDACi had been able to reduce TDP43 induced 
mortality. 
 
Figure 34.Molecular formula of HDACi Sodyum butyrate (on the left) and Trichostatin A (on the 
right). 
 
4.6.1.1  HDACi Sodyum butyrate and Trichostatin A reduce TDP43 induced mortality 
As described in Materials and methods, we treated TDP43 expressing cells with two 
different concentration of HDACi NaB, i.e. 0.2 mM and 0.04 mM, at the moment of the 
transduction and 24 hours later. We measured cells vitality 48 hours after transduction. 
We observed a statistically significant increase of vitality in cells treated with 0,2 mM 
of NaB, reaching, in some case, non infected cells vitality levels. 0,04 mM NaB induces 
a milder effect (Figure 35, panel B).Trichostatin A has a similar effect when used at the 
final concentration of 25 nM; on the contrary, 10 nM of TSA doesn‟t have any effect on 
survival(figure 35, panel C). 
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Figure 35. HDAC inhibitors Sodyum butyrate and Trichostatin A ameliorates cells viability in cells 
overexpressing TDP43 pathological mutant forms. A) Experimental approach. SHSY-5Y cells were 
plated on a 96-well multiplate dish and transduced 24 hours later with adenoviral vectors carrying TDP43 
WT or mutant forms (M337V or A382T). Cells were treated immediately with HDACi after the 
transduction and then treated again 24 hours later. 48 hours after transduction, cell viability was analyzed 
as illustrated in materials and methods. B) SHSY-5Y cells treated with NaB 0,2 mM show an increase in 
cell viability, especially in those transduced with mutant TDP43 (black arrows). C) TSA 25 mM induce 
ameliorates cells viability in cells overexpressing mutant TDP43 (black arrows).   
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5.1 ALS AND EPIGENETIC ALTERATIONS 
Several evidences indicates that in ALS in patients as well as in cellular and animal 
models there are remarkable alterations in the epigenetic equilibrium. The epigenetic 
hypothesis of ALS finds in the alteration of acetylation/deacetylation balance of 
histones tails a possible explanation for the pathogenesis. A decrease in global 
acetylation levels of histone H3 and H4 has been well described. A possible explanation 
of this phenomenon is the decrease in the expression levels of CBP/p300, one of the 
principal histone acetyltransferase. This decrease is not casual. It has been observed a 
severe deacetylation of the promoter of pro-survival genes, which leads to a decrease in 
transcriptional activation, and a contemporary increase in acetylation of lysine residues 
of histone tails in the promoter of pro-apoptotic genes.  
DNA methylation is an another epigenetic pathway that has been linked to ALS 
pathogenesis. A significant body of literature evidences that in ALS there is a 
significant upregulation of some de novo methyltransferases (DNMTs), especially 
Dnmt1 and Dnmt3a, leading to an increase in DNA methylation. The increase in DNA 
methylation is a marker of transcriptional repression. 
Up to now evidence of alterations in global acetylation and deacetylation levels were 
obtained mainly in ALS models linked to SOD1. For this reason, I have dealt with 
generating and characterizing ALS cellular models in which the transient expression of 
fALS causative genes is mediated by high titer infectious recombinant adenoviruses. I 







. I demonstrated that cell viability is reduced in neuronal cell 
lines that express SOD1, FUS and TDP43 genes, and so I confirmed that our model is a 
good model of fALS. Transgenic mice SOD1
G93A
 was our animal model of fALS. Then, 
I selected histonic markers linked to transcriptional activation (phospho-acetylation on 
serine 10 and lysine 14 on H3 tail- H3-K14acS10ph,  and the dimethylation of lysine 4 
on H3 tail- H3K14me2), or to transcriptional repression (the trimethylation of lysine 9 
on H3 tail). I performed western blot analysis of total protein extract and 
immunofluorescence analysis on spinal cord of transgenic mice. In addition, I  
measured global DNA methylation on genomic DNA from transduced cells.  
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Analyzing histonic markers, I could observe a severe significant reduction in 





. Concerning SOD1, I observed a specular increase in 
transcriptional repression marker 5metCyt, in cells expressing SOD1
G93A
. This lead us 
to speculate that there is a close link between SOD1 pathological mutations and 
epigenetic alterations. 
On the contrary, I couldn‟t observe any significant reduction in transcriptional 
activation marker in cells expressing pathological mutant forms of FUS and TDP43. I 
observed, in both cases, a significant increase in transcriptional activation marker 




This is probably why the 
pathological link between FUS, TDP43 and motor neuronal cell death is not directly 
linked the epigenetic alterations analyzed.  
I were also able to demonstrate that the levels of transcriptional activation markers H3-
K14acS10ph and H3-K4me2 are significantly reduced also in vivo, in a ALS mouse 
model, the transgenic mice SOD1
G93A
.  
Further analysis could clarify the link between SOD1 and the epigenetic machinery. 
 
5.2 TDP43 AND HDAC1: POSSIBLE FUNCTIONAL ROLE OF THEIR 
INTERACTION 
Starting from the evidence that FUS interacts with HDAC1 on DNA damage sites and 
considering that FUS and TDP43 share many functional domains, I decided to verify if 
also TDP43 could interact with HDAC1. It is important to consider also that TDP43 
directly interact with HDAC6, as illustrated in Introduction, paragraph 1.2.3, and is 
deacetylated by this histone deacetylases. Starting from these evidences, by co-
immunoprecipitation experiments between TDP43 and HDAC1 I was able to 
demonstrated that, as FUS, TDP43 WT interacts with HDAC1 in cellular models of 
ALS. I moved on this way and I could observe that also pathological mutant forms of 
TDP43 (M337V and A382T) in vitro interacts with HDAC1. By immunofluorescence 
experiments, I confirmed that TDP43 and HDAC1 co-localize into the nucleus is 
SHSY-5Y and SHSY-5Y-HDAC1 cells. 
Alessandra Masala 
Epigenetic modifications associated with Amyotrophic Lateral Sclerosis (ALS) onset and progression 
PhD Thesis in Biomolecular and Biotechnological Sciences 
University of Sassari 
 86 




 interacts with HDAC1 as well 
as TDP43
WT 
, I looked at HDAC1 enzymatic activity in the presence of TDP43, in 
SHSY-5Y and SHSY-5Y-HDAC1 cells. Even if I observed a trend in both cell lines in 
which it seems that the enzymatic activity changes in the presence of mutated TDP43, I 
couldn‟t prove any significant difference in HDAC1 enzymatic activity in presence of 
TDP43.  
To further understand how this interaction is mediated, I built up five TDP43 deletion 
mutants, lacking of 1 or 2 functional domain: Δ N-terminal, Δ-RRM1, Δ-RRM2, Δ-G-
rich, Δ-RRM1/RRM2. I analyzed the interaction between these truncated forms of 
TDP43 and HDAC1 by co-immunoprecipitation techniques, and these data revealed that 
the only mutant that doesn‟t interact with HDAC1 is the double deletion mutant  lacking 
both the RNA binding domains (Δ-RRM1/RRM2). Thanks to this data, I demonstrated 
that TDP43 interacts with HDAC1 via its RNA binding domains RRM1 and RRM2. 
Starting from the evidence that TDP43 does not alter HDAC1 enzymatic activity, 
according to these evidences, I decided to analyze the effect of TDP43 and HDAC1 on 
cell viability. I observed that the co-expression of  pathological mutant forms of TDP43 
and HDAC1 in SHSY-5Y cells have a synergic effect in decreasing cellular viability, 
compared to cells expressing only TDP43. Furthermore, I confirmed this data also in 
cells stably expressing HDAC1 (SHSY-5Y-HDAC1 cell line).  
Taken together, this data permitted us to imagine a model of the pathological role of 
TDP43 in ALS, in which TDP43 and HDAC1 can possibly interacts on promoters on 
DNA, and alter gene transcription mediating a change in acetylation/deacetylation 
equilibrium.  This data is in accordance with what observed in the reduction of H3 
acetylation in cells expressing SOD1
G93A/H80R
. This model needs to be confirmed by 
several other experiments. 
Even if I could demonstrate that TDP43 interacts in vitro with HDAC1 via its RRM1/2 
domain, many points remain unclear. It will be necessary to verify if TDP43 and 
HDAC1 interacts also in vivo. Then, it will be interesting to analyze the functional 
aspect of this interaction and verify if our proposed model can be confirmed. One 
possible perspective can be to study if TDP43 and HDAC1 interacts on gene promoters 
by chromatin immunoprecipitation.  
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Future studies should analyze the role of TDP43 as a transcription factor, by luciferase 
assay on a predicted promoter.  
In addition, it will be necessary to analyze the role of TDP43 in splicing of selected 
genes. 
Finally, one possible point to clarify could be if HDAC1 directly deacetylate TDP43, 
analyzing TDP43 acetylation pattern by 2D gel electrophoresis, to discover if this 
covalent modification can be the signal that alter TDP43 functions. This last point may 
lead to clarify if TDP43 and HDAC1 interaction is direct and TDP43 is deacetylated by 
HDAC1, or if the interaction is indirect and they co-interact with other proteins in a 
chromatin remodeling complex. 
5.3 HDAC INHIBITORS IMPROVE VITALITY IN ALS CELLULAR MODELS 
HDAC inhibitors Sodium butyrate (NaB), Sodium Valproate (VPA) and Trichostatin A 
(TSA) have been widely studied as potential therapeutic resources in ALS treatment. 
Despite many promising preliminary data and clinical trials, they didn‟t proved any 
consistent therapeutic improving.  
Starting from this unhopeful assumptions, I decided to analyze the effect of HDAC 
inhibitions in cellular models of ALS, in particular in TDP43 ALS model. I were 
particularly interested in the effect of HDAC inhibition, not in the possible therapeutic 





.  In particular, they are able to restore cellular vitality at 
the levels of non infected cells.  
This enthusiastic in vitro preliminary data doesn‟t consider any of the possible problems 
in using HDACi in therapy, but they can be an interesting starting point.  
To confirm the possible therapeutic effect of reducing HDAC activity, further 
experiments will be necessary. For example, it will be interesting analyzing the effect of 
the inhibition of HDACs mediated by RNA interference. 
Anyway, more therapeutic inhibitors, specific for one HDAC, will be more adapt to 
study.  
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Finally, to confirm this data, it will be necessary to analyze if this therapeutic effect is 




The vulnerability of motor neurons to neurodegeneration in ALS patients cannot be 
explained by considering separately genetic causes and environmental risk factors. On 
the contrary their contribution to post-transcriptional changes or epigenetic mechanisms 
can probably be crucial to understanding ALS pathogenesis, and establishing a path to 
treatment. The data presented in this PhD thesis indicates that is worthwhile to 
investigate the link existing between a determined epigenetic modification and a single 
ALS-causing gene, to identify an effective "epigenetic therapy".  
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